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The purpose of this study was to investigate both the non-motor features associated with 
Parkinson's disease (PD), i.e. anxiety and depression, and these features impact the efficacy of a 
mild exercise intervention treating sleep dysfunction and other non-motor symptoms, as well as a 
gait impairment.  To determine the prevalence and comorbidity of depression and anxiety 
symptoms and their relationship with disease progression, a retrospective database analysis was 
performed using data collected during the routine evaluations of 1221 patients diagnosed with 
PD performed during the initial visit to a PD clinic. Given the discrepancy in previous estimates 
of mood symptoms in PD, it was hypothesized that 50% of the population would demonstrate 
anxiety or depression symptoms and that severity of these symptoms would correlate with 
overall disease severity.  Anxiety and depression symptom severity was measured with 
respective Beck scales, while disease duration (years since PD diagnosis), Hoehn and Yahr (HY) 
stage, and Unified Parkinson's Disease Rating Scale (UPDRS) scores assessed modes of disease 
progression.  Anxiety and depression were analyzed in categories of severity, prevalence, and 
strength of relationship with respect to disease progression markers using correlational analysis 
and chi-square tests.  Results of the database analysis confirm previous findings that anxiety and 
depression are relevant non-motor symptoms of PD as well as the hypothesis, where more nearly 
half the sample population was determined to have significant depression while two-thirds 
reported anxiety symptoms.  While the severity of mood symptoms was found to be worse in 
patients with greater disease progression, this relationship was found to be non-linear. 
A randomized controlled pilot clinical trial was then completed to assess the impact of 
mood disorders on the efficacy of a mild exercise intervention- Qigong meditation- on the non-
motor symptoms of PD especially sleep quality, fatigue, and cognitive impairment, as well as 
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gait performance. Previous studies have found that mood symptoms negatively affect adherence 
with interventions for treating symptoms of PD. In a previous pilot study conducted in our 
research laboratory the practice of Qigong meditation improved sleep, fatigue, cognition, as well 
as gait performance in PD; however, there was no control group and the sample size was small. 
We hypothesized that the current pilot study would find significant improvements in the 
experimental group compared to the control group and in terms of non-motor symptoms, 
especially sleep quality, and gait performance compared to the control groups, and that mood 
disorders in participants might decrease efficacy of the intervention. During six weeks of 
intervention, both a control and experimental group performed the mild/Qigong exercise twice 
daily in addition to a weekly group session.  While both groups performed the same body 
motions of the exercise, only the experimental group synchronized their breathing, sounds, and 
meditation with the movements.  Non-motor symptoms in PD were assessed using standard 
evaluations. The effect of mood symptoms on efficacy of the intervention was primarily 
measured by the rate of compliance demonstrated by study participants reporting a history of 
anxiety/depression. Based on a thorough examination of potential technologies for measuring 
gait pattern, A Gaitmat II device was selected and used to quantify gait velocity, stride time, 
stride and step length.  As hypothesized, participants in the experimental group reporting a 
history of anxiety/depression reported lower overall compliance with the exercise program than 
fellow participants. Further, patients in the experimental group demonstrated significant 
improvement in sleep quality compared to the control group while both groups improved gait 
performance and some autonomic symptoms including urinary and sexual functioning. Fatigue 
also improved in the experimental group, though not comparatively significant.  
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The study findings suggest the Qigong exercise may be a viable complementary therapy 
for treating both non-motor symptoms (NMS) and gait impairment of PD, especially sleep 
dysfunction. Further, mechanisms associated with the practice of Qigong may specifically slow, 
halt, or even reverse neurological damage associated with PD, given the neurodegenerative 
association with the PD symptoms improved in the study.  Both the database analysis and pilot 
clinical trial suggest mood disorders are prevalent non-motor symptoms in PD, and that 
addressing these aspects is integral for providing adequate care to persons with PD and optimize 
the benefit of alternative therapies such as Qigong exercise in treating non-motor and motor 
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Chapter 1: Introduction 
 In 1817, Dr. James Parkinson first identified a disease he called the “shaky palsy,” a 
condition known today as the neurodegenerative disorder that bears his name, Parkinson’s 
disease (PD).[1] With 60,000 new cases diagnosed each year, between seven and 10 million 
people are affected by PD worldwide. While symptoms are both motor and non-motor, classic 
characteristics of the disease consist of resting tremor, rigidity, akinesia and/or bradykinesia, and 
postural instability.[2]  A clinical diagnosis of PD is made based on the presence of bradykinesia 
and either distal resting tremor or rigidity, as assessed by a physician.[3] However, a completely 
accurate diagnosis of PD can only be made by autopsy by confirming the presence of neuronal 
inclusion bodies (Lewy bodies) in the basal ganglia.  No means of accurately detecting Lewy 
bodies in patients exhibiting asymmetric cardinal symptoms of PD can lead to incorrect 
diagnoses of the disease.[4] In fact, PD is considered underdiagnosed in the general population 
due to both misdiagnosis and late diagnosis.[5] While environmental factors and family history 
are thought to elevate the risk for developing PD, predicting persons who are at high risk for PD 
remains elusive.[6] 
Living with PD comes with undergoing a wide range of symptoms, which include both 
motor and non-motor features.  While much variety exists in the experience of type, duration, 
and severity of these symptoms, they all impact daily functioning and overall quality of life in 
persons diagnosed with PD. In addition to stooped posture and reduced arm swing, other gait-
related features of the disease include reduced speed and stride length. This combined gait 
instability predisposes persons with PD to falls, which are associated with severe injury and even 
mortality.[7] In addition to the motor features, non-motor symptoms of mood disorders, sleep 
quality, and thinking abilities are of particular concern in PD.[2] 
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 The kind and severity of impairment resulting from these symptoms can vary 
significantly throughout the course of the disease. For persons in the early stages of PD, primary 
symptom complaints consist of slowness, tremor, stiffness, pain, and loss of smell and/or taste. 
Persons with advanced PD have identified the five most problematic aspects of the disease as the 
wearing off of medication, changes in mood, drooling, sleep disturbances, and tremor as the most 
problematic features of the disease.[8] Despite many therapies, PD consistently worsens with 
time and the mean age of death is in the mid-seventies regardless of age of onset or disease 
management.[2]  
 While non-motor symptoms (NMS) of PD impact daily living, contribute to disability, 
and decrease life expectancy, they are less readily recognized and too often untreated.  Further, 
these non-motor symptoms in some cases impact quality of life more than PD motor symptoms, 
and may pre-date the onset of motor symptoms in PD. [9, 10] NMS include but are not limited to 
constipation, pain, psychosis, impaired cognition, sleep disturbances, and mood disorders.[11] 
Mood disorders, specifically anxiety and depression have received increased attention for their 
effect on quality of life in PD.  [9, 10] 
 The standard treatment of PD symptoms include carbidopa/levodopa, dopamine agonists, 
monoamine oxidase-B (MAO-B) inhibitors.[2] Anti-depressants, which include selective-
serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), and 
tricyclic anti-depressants (TCAs), are standardly prescribed as treatment for mood disorders in 
PD.[12]  
Neurodegeneration resulting in PD symptoms: While a diagnosis of PD is based on the 
manifestation of external symptoms, a pre-clinical period of neurodegeneration is characterized 
by loss of dopamine neurons coupled with forebrain dopaminergic denervation.  This 
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neurodegeneration occurs primarily in the substantia nigra pars compacta of the basal 
ganglia.[13] The large, neuronal cell bodies in the substantia nigra pars compact produce and 
store all the components necessary for producing dopamine, the neurotransmitter necessary for 
regulating body movement.[4]  By the time of diagnosis, a patient is estimated to have lost 30% 
to 50% of nigrostriatal neurons.[13, 14]  
 The duration of this pre-clinical period, that is, the length of time between the start of 
neurodegeneration and the manifestation of motor symptoms, is generally unknown in most 
patients.  While much variability exists between persons as to the rate at which this degeneration 
occurs during the pre-clinical interval, [15] the range of this duration is estimated to be three to 
15 years prior to observable motor symptoms.[6]  The younger the age of disease onset, the 
longer this period is estimated to be.[13] 
 After disease onset, interruptions in interactions between the serotoninergic, 
dopaminergic, and norepinephrinergic systems are thought to characterize the neuropathology of 
PD.[16] More specifically, evidence suggests loss of norepinephrine from the locus coeruleus, 
with decreases in both the number and activity of norepinephrine neurons, is integral to the 
pathophysiology of the disease.[17] Evidence points to damage rendered to 5-hydroxytryptamine 
(5-HT), which is correlated with enhanced tremor and decreased serotonergic functioning, and 
norepinephrine systems is associated with advancing severity of PD.[12]  
Motor Symptoms 
Cardinal Motor Symptoms: The traditional markers of PD, motor symptoms present challenges 
to a patient’s wellbeing and quality of life and their onset is typically asymmetric.[3] As 
previously mentioned, four primary cardinal motor symptoms are recognized as characterizing 
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the disease: resting tremor, rigidity, bradykinesia/akinesia (slowed/involuntary movement, 
respectively), and postural instability, though the latter of which is often not present in the initial 
stages of the disease. While these cardinal features are considered to result from dopaminergic 
system dysfunction, tremor may also be caused by non-dopaminergic degeneration also 
associated with PD pathology.[18]  
Resting tremor, as assessed between 3 and 7 Hertz, is frequently the first motor symptom 
experienced in PD and can worsen with anxiety or tasks requiring walking. [3, 14] The rate at 
which severity of motor symptoms increases varies based on overall disease progression and 
disease duration. Typically, gait and postural instability develop later in the disease, whereas 
tremor remains fairly constant throughout the disease.[15]  
Currently, the Unified Parkinson’s Disease Rating Scale (UPDRS) is the gold standard 
assessment for measuring a patient’s overall disease status with regard to mental, daily activities, 
motor, and treatment response facets of the disease.[3] Besides walking, PD motor symptoms 
can impair performing skilled motor tasks such as writing (micrographia) or speaking.[3, 19] 
Daily activities and capacity to work can be greatly inhibited by bradykinesia and affected 
dominant hand.[3] Motor symptoms can become unpredictable and fluctuate due to the wearing 
off of PD medication.[3] Not surprisingly, decreased physical activity, evident in PD patients is 
associated with a decline in physical functionality and is intensified by aging.[20] 
Neurodegeneration related to motor symptoms: Loss of motor skills and involuntary movements 
in PD otherwise described as dopaminergic symptoms, can be primarily attributed to dysfunction 
in the basal ganglia.[19] More specifically, motor symptoms result from dopaminergic neuron 
loss in the substantia nigra parts compacta, decreasing the input of dopamine to the striatum and 
thereby altering the response of the globus pallidus, thalamus, sub-thalamus, and substantia nigra 
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pars reticularis. Lewy bodies and neurites, which consist of byproducts of the neurodegeneration, 
develop in the substantia nigra and are also found in the locus ceruleus, brainstem, vagus, 
amygdala, and hippocampus. Mutations in the alpha-synuclein gene are thought to cause 
autosomal dominant, PD; the presynaptic neuronal protein alpha-synuclein, is implicated in the 
development of neurodegeneration in PD.[21] Nevertheless, the underlying pathogenesis of gait 
hypokinesia, akinesia, and dyskinesia are thought to be different, given the asymmetric 
development of these features with respect to disease progression.[19]  
Standard treatment for motor symptoms of PD: The dopaminergic medication levodopa 
combined with carbidopa is the standard treatment for motor symptoms, while dopamine 
agonists are also introduced early on in the disease in order to slow motor disability.[3] In earlier 
stages of the disease, drugs modulating catechol O-methyl transferase and MAO-B may be 
introduced and used throughout the course of the disease. Less commonly used are 
anticholinergic agents, which are primarily prescribed to younger patients with severe resting 
tremor and functioning cognitive faculties, can pose gastrointestinal and psychiatric side effects. 
[3] Imbalance in pharmacological treatment result in the slowing of and greater difficulty 
performing movements. [19] 
The short and long-term effects of standardly prescribed medication for PD remain 
controversial. Several studies with varied methodology report the use of medication increases 
survival time and control motor symptoms, especially at the latter stages of the disease.  [22] 
However, non-motor symptoms are typically less responsive than motor symptoms to 
dopaminergic therapy.  [2] Furthermore, standard pharmacological care may at times fail to treat, 
cause, or exacerbate NMS associated with PD. [23] Given that dopaminergic drugs commonly 
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result in daytime sleepiness and insomnia, some studies suggest dopaminergic drugs promote 
sleep if they are needed to carry a patient through the night. [24] 
Gait Impairment: Considered a motor symptom in advanced PD, gait impairment can 
increase the risk of falling and lead to injuries, loss of independence, and increased mortality.[7, 
25, 26] Gait complications are common in PD, resulting from the progressive loss of dopamine 
producing cells in the basal ganglia. The absence of dopamine ultimately results in the loss of 
gait automaticity [27]. The characteristics of PD gait result from the combined effects of the 
fundamental motor symptoms discussed previously, resulting in a gait pattern with reduced arm 
swing and trunk rotation; forward stooped posture; reduced motion at the hips, knees, and ankles; 
slowness; reduced step size; and low ground clearance [28]. While persons with PD can often 
walk in a straight line with ease, tasks requiring turning, simultaneous mental and motor 
faculties, and navigating obstacles in a community setting can be remarkably difficult. 
Maintaining balance is another common difficulty in PD, which affects a person’s safety and the 
ability to walk independently. Persons in the advanced stages of the disease have greater 
difficulty maintaining balance. The struggle to maintain balance is due to a compromised ability 
to maintain one’s center of mass above a narrow, shifting base of support while walking, 
resulting in postural instability.[29]   
One of the most prominent features of PD gait is a significant reduction in gait velocity. 
Morris, et al. [28] found that patients with PD walked with a velocity range between 0.67 – 1.0 
m/s, compared to a pace of 1.25 – 1.5 m/s in healthy controls. The change in walking speed is 
generally considered a direct result of significant reduction in stride length, a key measure in PD 
progression. Stride length appears to have a significant correlation to motor UPDRS scores, 
where more drastic reduction in stride length indicates more severe impairment [30]. Flat-footed 
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walking and reduced joint range of motion in the lower limbs results in diminished vertical and 
frontal ground reaction forces, especially during push-off. This results in reduced movement 
amplitude, which occurs across all joints of the lower extremity [28].  
Postural instability is another major feature of gait impairment in PD that may lead to a 
high incidence of falling, ranging from 38% to 62% in patients with PD over a one-year period. 
[28, 31] One indicator of postural instability is the increased time in double support [29]. 
Typically, time in double support falls in the range of 20% to 30% of the gait cycle, but may be 
increased to over 35% in PD patients [28]. There are other measures of gait and postural 
instability in patients with PD have been shown to improve as a result of interventions, including 
functional reach test [30], chair rise and one-leg stance [20], an variability in stride length and 
stride time [30, 32, 33].  
The most common movement disorder in PD is hypokinesia, in which persons movements 
are both slower and smaller in size.[28]  Patients with PD typically walk slower than non-PD 
persons of a similar age as measured by gait velocity.  While cadence (the average step rate) may 
not be affected, persons with PD also take shorter steps as measured by stride length, two-thirds 
the length of controls on average, which can result in tripping.[7, 19] Reduced push off reaction 
forces, where PD patients walk with a flat-footed gait pattern and expend more energy when 
initiating gait, may also increase risk for tripping in PD.[19] Thus, reduced gait speed, shorter 
step and stride lengths along with stooped posture prominently characterize the gait impairment 






While not considered cardinal features of PD, non-motor symptoms can result in disability 
and significantly affect overall quality of life for those with PD. [2, 8] Development of non-
motor symptoms may precede the onset of traditional PD motor symptoms by years and tend to 
worsen with disease progression.[21, 24]  Specifically, the NMS of mood disorders, constipation, 
and sleep problems may appear early on or even precede the development of PD motor 
symptoms. [8, 24] Another common NMS frequently subtle but present in the early stages of the 
disease is cognitive decline, which can be difficult to detect. Impaired cognition emerges as 
deficits in executive functioning, working memory, and visual-spatial capacity and worsens with 
disease progression.[21] Decreased dopaminergic innervation in nigrostriatal and mesocortical 
dopaminergic systems related to altered frontal cortex functioning.[21]  An estimated 90% of 
persons diagnosed with PD suffer from NMS.[2] While NMS have received more attention in 
recent years, they can still negatively affect management and care of the disease.[2] The 
relationship between disease duration and certain NMS in PD will be examined further in this 
paper. 
 NMS characterizing the pre-motor symptom stage of PD include olfactory dysfunction, 
constipation, sleep fragmentation, mood disorders and Rapid Eye Movement (REM) Sleep 
Behavioral Disorder (RBD).[21, 24] Increasing attention given to identifying the NMS in this 
stage of PD has developed.[24] The role neurodegeneration plays with respect to the 
development of NMS during the pre-motor stages of the disease still remains unclear and 
continues to be a matter of study.[21] As noted, dopaminergic system dysfunction is implicated 
in the development of motor symptoms, yet many non-motor symptoms are attributed to deficits 
in non-dopaminergic mechanisms.[13] Even still, the neuroanatomical pathways responsible for 
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NMS remain largely unknown, making for discussion of NMS pathophysiology mostly 
speculative.[11] 
Autonomic symptoms: Broadly defined as autonomic symptoms, these complications can include 
constipation, urgent urination, excessive salivation, and sexual dysfunction.[2, 14] The risk for 
developing these NMS in PD increase with respect to greater age, overall disease severity, and 
higher doses of dopaminergic medication.[2] The neurodegeneration of these symptoms can be 
attributed, in part, to Lewy bodies in the peripheral autonomic nervous system.[14]  
Anxiety and Depression in PD 
 Mood disorders, specifically anxiety and depression have long been associated with PD.  
Dr. Parkinson himself noted a certain melancholy in his patient who suffered from the shaking 
palsy.[1] With regard to anxiety, the most common forms in PD are panic disorder, generalized 
anxiety disorder and social phobia, with anxiety being more associated in patients with 
symptoms of postural instability and gait dysfunction than tremor-dominant patients.[34] 
Symptoms of anxiety were found to affect quality of life in non-demented PD patients, even 
more than depression, cognition, or motor symptoms.[9] Thought to affect motivation and 
cognition, anxiety in PD can exacerbate PD motor symptoms and impact overall treatment 
compliance.[9]  
 Hypotheses as to whether anxiety is a reaction to living with the disabling motor 
symptoms or endogenous to PD neuropathology have emerged as means of explaining anxiety in 
PD.[35] Social anxiety may develop in patients as a result of embarrassment caused by their 
motor symptoms emerging during social situations.[36] However, symptoms of anxiety may in 
fact predict the onset of PD, as persons pre-disposed to an anxious personality are associated 
18 
	
with a greater risk for developing PD.[10]  Mood disorders, may then in part, prefigure the 
development of PD.[23] The development of anxiety symptoms several years prior to a diagnosis 
of PD during the pre-motor stage would suggest the neurochemical changes associated with PD 
are implicated in the cause of anxiety in PD.   
 The loss of both dopaminergic and serotonergic innervation, both associated with PD 
neuropathology, has been demonstrated to correlate with both anxiety and depression 
symptoms.[12] Further, serotonergic dysfunction has generally been implicated as the cause of 
most mood disorders. While patients with PD exhibit progressively diminished functioning of 
the serotonergic system, the rate of degeneration is non-linear and thus varies between patients. 
Although the exact pathophysiology remains unknown, degeneration in the locus ceruleus, as 
well as its dorsal ascending noradrenergic pathway may result in anxiety symptoms.[12, 37] 
Furthermore, anxiety may also be affected by dopamine levels, and therefore intrinsically linked 
to PD.[38] Reduced functioning in the limbic noradrenergic and dopaminergic systems has been 
shown to correlate with both anxiety and apathy in non-depressed patients. [13]  
 While serotonergic denervation in PD usually begins in the caudate, thalamus, 
hypothalamus, and anterior cingulate cortex, the denervation spreads to the basal ganglia, limbic 
system, and cortex as the disease progresses.[13] A study employing transcranial sonography has 
revealed abnormalities in the substantial nigra, as marked by hyperechogenicity, previously 
associated with PD, is also a common feature of depression in the general population.  The 
findings concluded persons with depression are three more times likely to develop PD in their 
lifetime.[39]  Further, anxiety has been postulated to even be one of earliest manifestations of 
PD. [40] Regardless of the exact causes, anxiety in PD is a reflection of the combined 
psychological and physiological conditions of the disease. [41]  
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 While anxiety may precede a diagnosis of PD, disparate claims have been made on 
whether anxiety worsens along with disease progression.[40] Two studies found no significant 
relationship between the severity of motor symptoms and anxiety, while another found anxiety 
symptoms were associated with increased motor impairment.[34] Younger age of onset has been 
associated with higher levels of anxiety, though anxiety disturbances tend to decrease with 
age.[34]  
 Much discrepancy exists in the estimates of persons with PD who experience relevant 
anxiety and depression symptoms.[40] Previous studies report the prevalence of anxiety in the 
PD population to be as low as 5%, while others as high as 75%.[9, 16, 35, 40, 42]  As the most 
explored mood disorder in PD, depression has been found to be the best predictor of quality of 
life in PD patients as measured by activities of daily living scales and is associated with greater 
motor disability.[9, 16, 43]  While nearly 50% of persons with PD are thought to be affected by 
symptoms of depression, much variance exists in the estimation of this prevalence.[16, 43] Due 
to negative social stigma associated with mood disorders, estimates of both anxiety and 
depression in PD may be under-reported.[5]  
Treatment of anxiety and depression in PD: Drugs acting on the serotonergic system, namely 
SSRIs and tricyclic antidepressants (TCAs) are the current standard care for managing anxiety 
and depression in PD. Most of these drugs elevate extracellular 5-HT levels by blocking their 
reuptake in their post-synaptic receptors, which are implicated in mood disorders.[44] The 
prevalence of use of anti-depressants and anxiolytics for the purpose of treating anxiety and 
depression also remains unclear.  While a study found 11% of its participants reported using anti-
depressants, another discovered 19% and 24% of its experimental and control groups, 
respectively used anti-depressants at the start of the study.[45, 46]  However, by the end of the 
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intervention of a mind-body exercise, the experimental group’s rate of use dropped to 16% while 
the control group increased to 33% 12 months later. [27] 
 While SSRIs are often employed in PD for treating mood disorders due to their relatively 
low side effects, a study found no significant benefit of SSRIs when tested against a placebo.[36] 
With the exception of older patients or those with severe depression, these medications are 
suggested to treat depression less effectively in persons with PD when compared to non-PD 
depression. However, these findings have been criticized for their small number of subjects (type 
II error), and there is a general lack of randomized control trials testing treatment of mood 
symptoms in PD.[47, 48] Although still considered by some to be an effective treatment for 
depression in PD patients, why SSRIs sometimes fail to curb depression symptoms in PD 
remains unexplained.[17] Conversely, a recent study found anti-depressants (SSRIs and TCAs), 
often used to treat both anxiety and depression, moderately improved mood symptoms in 
PD.[49] Nonetheless, well designed trials testing the efficacy of anxiolytics and anti-depressants 
for treating mood symptoms in PD are still lacking.[23, 36] Since mild depression is thought to 
account for the majority of depression in PD, non-pharmacological interventions are a preferred 
choice for therapy, which can include counseling, education, and cognitive behavioral 
therapy.[23]  
 Nevertheless, anxiety and depression symptoms may inhibit the efficacy of treatment 
interventions for both the mood symptoms themselves and PD symptoms in general in persons 
with PD. The presence of depression has been found to negatively correlate with adherence to 
antiparkinsonian therapy adherence as well as for medication in the general population.[50] 
Lower rates of compliance with a home-based exercise program in persons with anxiety, 
depression, or mental health problems were reported in a study.[50]  Further, a particular form of 
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anxiety in PD referred to as “medication phobia” has been proposed to describe tendencies in 
which persons with PD avoid taking prescribed medication due to an irrational fear of it.[51] 
Sub-optimal compliance with anti-parkinsonian treatment has been identified as highly prevalent 
in the PD population, which is associated with an overall worsening of PD symptoms.[52]  
Sleep Dysfunction 
Sleep dysfunction is commonly associated with PD, significantly lowering patients’ 
overall quality of life. [2, 24, 43] Dr. James Parkinson also identified sleep disturbances as a 
symptom of PD in his original description of the disease.[53] More common in PD populations 
compared to the elderly population, sleep dysfunction in PD frequently consist of daytime 
sleepiness, insomnia, night-time waking, restless leg syndrome (RLS), vivid and/or violent 
dreams, sleep apnea, and periodic limb movements during sleep (PLMS).[14, 17, 21, 24, 43, 54]  
Among patients with advanced PD, sleep disorders (most commonly insomnia), daytime 
sleepiness, and daytime sleep attacks (though rare and often due to side-effects of medication) 
have been considered one of the top most prevalent symptom complaints.[8, 24]  Additionally, 
waking during both the night and early morning are commonly caused by resting tremor, with up 
to 98% of patients suffering from a range of these sleep disorders.[2, 24, 53] Bradykinesia may 
also result in disturbed sleep, due to patients’ inability to turn in bed.[17] 
Perhaps the most challenging sleep disorder in PD is REM Behavior Disorder (RBD), 
which is characterized by a lack of normal atonia (muscle control) during REM sleep.[6] 
Occurring in approximately a third to a half of persons with PD, RBD will frequently enact vivid 
or unpleasant dreams.[24, 55] As many as 50% of persons with PD may kick or punch during 
REM sleep, potentially causing physical harm to both themselves and their bed partner.[56] RBD 
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is likely caused by neural damage in the REM sleep atonia system, resulting in a lack of muscle 
tone during REM sleep. [56] Further, brain imaging has revealed RBD is associated with 
cholinergic denervation. [13] The onset of RBD in PD is thought to occur before the onset of 
motor symptoms, where more than 50% of persons with RBD will develop PD an average of 13 
years after having RBD.[15] Other problems related to PD such as autonomic dysfunction, 
cognitive impairment, longer disease duration, and RLS have also been shown to be associated 
with RBD in PD.[15, 56]  
Sleep dysfunction is prevalent in all stages of the disease.  Problems with sleep are 
thought to begin early in the disease, even prior to motor symptoms by several years, and 
intensify as the disease progresses.[2, 8, 21, 53, 55] Quality of sleep as measured by deep, REM, 
and sum total sleep time has been shown to decrease in patients with respect to longer disease 
duration.[22] Daytime sleepiness frequency positively correlates with disease severity, treatment 
duration, and other NMS.[24] This progression may occur at a linear rate along with other NMS 
such as difficulties with cognition, speech, and gait.[22] Conversely, insomnia, another common 
sleep problem affecting up to 50% of the PD population, does not appear to worsen with respect 
to overall disease progression.[22, 24] In the early stages of the disease, nocturnal cramps and 
nocturia (waking due to the need to urinate) are commonly experienced.[53] Age may also be a 
factor, as older patients complain of shortened total sleep time and unwanted awakenings.[24] 
Sleep dysfunction can be difficult to distinguish from other NMS in PD due to symptom 
overlap.  Difficulties with sleeping can be mistaken for depression or vice versa in PD, as sleep 
dysfunction and depression are both associated with a patient’s immobility, psychomotor 
retardation, and apathy.[17, 23] Problems associated with sleep dysfunction such as lack of 
energy, insomnia, or daytime sleepiness may indicate a patient is depressed, when he or she in 
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fact is not.[17] However, anxiety and depression may both cause and worsen sleep disturbances 
in PD patients.[17, 53] Further, the worsening of depression has been associated with greater 
disability with respect to sleepiness.[55] Whether sleep disorders trigger anxiety and depression 
or if the vice versa is true remains an open question for discussion.[17] In addition to anxiety and 
depression, fatigue, cognitive impairment, neurodegeneration, and prescribed drugs, may all 
contribute to sleep disturbances in PD.[24] 
While little is known regarding the pathogenesis of sleep disturbances in PD, theories 
have emerged speculating on the symptom’s neuropathology. Sleep disturbances in PD are 
thought to be caused by multifactorial neuropathology specifically associated with lesions in the 
brainstem’s central sleep regulation centers in the raphe nucleus, as well as thalamocortical 
pathways affecting transmission of both dopamine and serotonin.[54, 55] Other regions in the 
brain regulating sleep are near the substantia nigra, where PD neurodegeneration traditionally 
occurs  may also be implicated in the development of sleep disturbances.[17] Dopamine neuron 
cell death itself may also negatively affect sleep quality, specifically in the midbrain’s ventral 
tegmental area, which is also involved in the sleep-wake cycle.[24] Dysfunction of the 
serotonergic system, which regulates sleep cycles is also associated with the neurodegeneration 
of PD and may be implicated in the development of sleep disorders, as well as other NMS 
including depression, fatigue, and visual hallucinations.[13] Nevertheless, thus far the role 
dopaminergic and serotonergic neuron degeneration plays in the development of particular sleep 
disorders in PD remains unclear.[24, 54] Additionally, PD patients with reduced mesopontine 
monoaminergic capacity have been shown via neural imaging to correlate with an inability to 
maintain REM sleep, thus resulting in difficulties with sleep.[13] 
 While diagnostic tools exist to identify sleep disorders in PD, symptoms are both under-
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recognized and lacking adequate treatment.[8] Despite sleep problems often predating motor 
symptoms in PD, the likelihood of sleepiness predicting the eventual onset of PD remains low as 
a predictive symptom. A study found only 9 out of 244 (less than 4%) of patients reporting 
sleepiness developed PD.[6] However, RBD may have greater potential as a predictive marker 
for PD, given that, as noted, 50% of persons affected by RBD are expected to develop PD or 
dementia within 10 years.[6, 24] Despite a need for more adequate care of sleep dysfunction, 
current care of PD may include the treatment of sleep difficulties. Nevertheless, dopaminergic 
treatment for motor symptoms as well as NMS medication (anti-depressants, anti-hypertensive 
drugs) may in fact result in further sleep difficulties.[17, 24] Further, common side effects of 
dopamine agonists include vivid dreaming, sleepiness, and sudden sleep attacks.[14, 54] The 
nonselective MAO-B inhibitor selegiline commonly prescribed to decrease the off-time of 
levodopa, has been implied to cause sleepiness, disruption of REM sleep, and sleep 
fragmentation, whereas the selective MAO-B inhibitor rasagiline has not be shown to 
significantly affect sleep quality.[24] 
Given that standard care may exacerbate sleep dysfunction symptoms, alternative 
therapies may assist in treating this NMS.  The practice of Qigong meditation has shown to 
improve sleep quality and decrease daytime sleepiness in patients with PD.[46] Tai Chi has also 
shown to improve both patients’ sleep quality as well as overall energy.[57] Other alternatives 
therapies that may improve sleep quality may include better sleep habits developed by sleep 
hygiene education, cognitive behavioral therapy specifically for insomnia (CBTI), and relaxation 
training. [24] 
Fatigue: Fatigue is another relevant NMS experienced by many persons diagnosed with PD. This 
NMS is perhaps the most disabling symptom of PD affecting the quality of life of up to one third 
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of persons with PD.[23] Often unpredictable in its onset, fatigue is characterized as the inability 
to initiate and sustain mental and physical activity, and is often exacerbated by physiological, 
psychological, and social stress.[23, 58] Patients with PD suffering from fatigue often describe 
the symptom as experiencing “tiredness,” “exhaustion,” and “lack of energy”. [58] Characterized 
by both mental and physical components, fatigue in PD affects all aspects of patients’ lives and 
can deter participating in and planning work, leisure, and social related activities.[58]  
Sometimes present before the development of motor symptoms in PD, fatigue has been shown to 
worsen with respect to disease progression, but is not necessarily correlated with motor 
dysfunction.[22, 23]  
 Like other aforementioned NMS in PD, fatigue is considered under-recognized and 
undertreated in PD. This is due in part to a wide variety of assessments and instruments used to 
diagnose fatigue in PD, many of which have not been validated, and perhaps also the intermittent 
nature of the symptom. [23, 58] Distinguishing fatigue from other NMS in PD is another 
challenge to recognizing and treating fatigue. Other NMS accompanying fatigue in PD include 
daytime sleepiness, cognition, apathy, and mood disorders.[23, 43, 54] Common characteristics 
of both fatigue and depression in PD include lack of energy as well as difficulties with 
motivation, concentration, and appetite.[23, 45, 59] Cognitive deficits are also associated with 
fatigue in PD; whether fatigue causes cognitive impairment or vice versa remains undetermined. 
[58]  
 While daytime sleepiness and fatigue may be considered similar in nature, studies 
suggest fatigue is an independent symptom of sleep disturbances in PD, though these symptoms 
are often co-morbid. Nevertheless, no studies have examined the sleep patterns of persons with 
PD in relation to fatigue. [58] Further, a relationship between motor symptoms, sleep disorders, 
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and fatigue remains inconsistent, nor has level of physical activity been shown to affect patients’ 
level of fatigue in PD. [23]  
 Rather than being attributed to other concurrent NMS such as depression or daytime 
sleepiness, fatigue worsens with respect to disease progression, and is thus primarily involved 
the pathological process specific to PD.[22] Conversely, dysfunction in the serotonergic system 
has also been suggested as a contributor to the development of fatigue as well as other 
accompanying NMS in PD. [13] Further, endogenous and exogenous factors are suggested to 
explain the co-morbidity of fatigue and other motor and NMS of PD, where the development of 
the disease and symptoms are inherently intertwined. [58] 
Non-motor Symptoms May Affect Gait in PD  
Gait impairment is viewed as a motor symptom of advanced PD. [25, 26] Growing 
evidence suggests a significant influence on gait by non-motor symptoms especially cognitive 
impairment and sleep disorder. Many motor features, including bradykinesia, rigidity, gait, and 
postural instability show strong correlations with cognitive decline [60]. This becomes 
increasingly evident during cognitively challenging situations [61-64]. Simple forward walking 
engages a high degree of automaticity in the absence of pathology. Normally, cortical 
engagement is needed only when the gait pattern, direction, or speed must change in response to 
environmental changes [65]. However, automaticity of normal gait is compromised in PD [66, 
67], often leading to increased reliance on cortical control [68, 69]. When cognitive dysfunction 
reaches a certain threshold, some patients may be unable to accommodate the increased cognitive 
demands to control walking.  
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Sleep disturbance in PD significantly affect clinical manifestations of the disease. PD 
patients with sleep disorder tend to have an increased frequency of falls and less clinical 
response to levodopa medication [70-72]. Rapid eye movement sleep disorder (RBD) is 
associated with slowness of gait [73]. Sleep disorder and abnormal gait pattern in PD may both 
involve the degeneration of nuclei in the rostral brainstem, primarily the pedunculopontine 
nucleus (PPN) [74]. The PPN plays a central role in gait and postural control as it generates the 
periodic locomotor activity and regulates central pattern generator in spinal cord [75, 76]. Focal 
lesions in the mesencephalic-pontine tegmentum, where the PNN is located, cause postural 
instability and loss of gait rhythmicity [77, 78]. PPN is also part of central circuitries and can 
modulate rapid eye movement sleep. Its dysfunction may lead to impaired maintenance of atonia 
and RBD [79, 80]. Improved sleep may help to alleviate dopamine sensitive symptoms [81]. 
 Conversely, improvement in cognitive function and/or sleep may lead to improve gait 
performance. In a study of elderly individuals who complained sleeping disorder, Tai Chi 
exercise showed greater improvement in overall sleep quality as well as in gait velocity and 
postural stability in comparison to a low-impact exercise program [82]. However, research 
evidence is lacking for supporting a notion that improvement in non-motor symptoms may lead 
to improvement in gait performance. A previous study in our research laboratory observed an 
improvement in sleep quality and gait performance in a group of patients with PD after the same 
intervention as used in the current study.[83] Our previous study, however, did not have a control 
group and was limited with a small sample size. We conducted the current randomized 
controlled pilot trial using the same intervention to confirm whether greater improvement in 
sleep, cognition, and gait performance could be observed after the intervention in the 




 Alternative therapies for treating symptoms of PD (those not relying on medication) 
include exercise, balance training, nutritional interventions, counseling, and education, which 
can all improve overall quality of life.[2, 3] Therapies encouraging social interaction and 
developing relationships tend to improve the overall wellbeing of persons with PD.  However, 
such therapies currently lack in existing PD rehabilitation programs.  [84] Exercise and physical 
therapy can effectively improve PD physical symptoms such as rigidity of flexed posture and 
develop flexibility, strength, and balance.  While exercise can offer therapeutic effects for the 
psychopathological impact of PD, the earlier such alternative therapies are introduced, the more 
effective they are.[2]  
Qigong exercise: Mild meditation exercises originating from Chinese medicine have been 
purported to improve quality of life in PD. The practice of one particular exercise, Qigong, 
which has been around for 5,000 years, is thought to activate naturally occurring physiological 
and psychological processes that improve one’s overall health and functionality. Similar to Tai 
Chi, Qigong incorporates focused breathing, slow movements, and meditation to attain a relaxed 
state, and the exercise may improve balance and decrease risk for falls. [20] Tai Chi and Qigong 
are closely related Chinese medicinal exercises, with similar theoretical framework, motions, and 
application for improving health.[20] Tai Chi has previously shown to improve outcomes in 
persons with PD.  Overall wellbeing and gait variability have been shown to improve with the 




 Similarly, Qigong is applicable as a therapy for PD patients since it can be easily adapted 
for patients with special needs such as balance difficulties. [46]  When compared to exercise 
interventions, a study showed Qigong improved quality of life in PD patients, but not 
significantly. [20] Qigong has also been shown to improve NMS in PD, especially sleep 
disturbances, but not autonomic and motor fluctuation symptoms. [46] While Qigong has been 
reported to improve psychological health, high blood pressure, pain, and immunity, few rigorous 
randomized trials have been performed to confirm the health benefits of Qigong on movement 
disorders such as PD.[86] Thus, the positive effects of exercise on PD symptoms remain 
controversial given that any treatment program may increase striatal dopamine release as part of 
a placebo effect.[46] 
Aim of Study 
Thus, the characteristics of non-motor symptoms in PD remain unclear regarding not only 
how prevalent and severe they are, but how they change throughout the course of the disease.  
While many treatments exist for primarily addressing the traditional motor symptoms of the 
disease, potential alternative, complementary therapies may also exist for treating certain non-
motor aspects of PD.  Even still, how effective these therapies may be for addressing particular 
symptoms, and how non-motor features, specifically mood symptoms, may limit the efficacy of 
such interventions in PD remain unknown.  
 With regard to non-motor mood symptoms in PD, the question is raised: how prevalent 
and severe are anxiety and depression in PD with respect to stage of the disease? Considering 
alternative therapy possibilities, another question can be asked: is Qigong exercise a viable 
alternative therapy for addressing symptoms of PD, especially sleep and gait dysfunction? 
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Synthesizing these two questions of interest, the following primary research question can be 
formulated: how do mood symptoms in PD impact the efficacy of alternative therapy program 
Qigong exercise program for treating motor and non-motor aspects of the disease?  
In order to examine the primary research question, a background research study will be 
conducted, which will investigate the prevalence and severity of anxiety and depression and its 
relation to disease severity in a general Parkinson’s population, based on retrospective data 
analysis.  A follow-up clinical trial with a between groups design will then be performed testing 
the effectiveness of the Qigong exercise therapy for treating non-motor and motor aspects of the 
disease, primarily sleep quality and gait functioning.  Study participants will be recruited for 
trial, and their level of anxiety and depression symptoms will be assessed in relation to efficacy 
of the exercise. 
The following hypotheses are put forth predicting the findings of the subsequent studies.  
It is predicted that greater disease severity will significantly correlate with increased severity of 
mood symptoms.  Given the results of pilot study testing Qigong exercise in PD, it is 
hypothesized that the experimental group will see statistically comparable improvement in both 
sleep and gait measures and corroborate these previous findings.  It would also be expected to 
see significant improvement in other symptoms of the disease such as cognition, fatigue, and 
mood.  Even still, it is further postulated that the Qigong exercise program will be less adhered to 
less by study participants with relevant mood symptoms. Thus, it expected that anxiety and 
depression will be found to be a significant non-motor symptom in PD, both regarding its 




Quantitative Measurement of Gait Impairment 
Technological tools for measuring gait pattern are of particular importance for this study 
investigating the positive effects of Qigong therapy in PD, given that biomarkers for gait 
functioning are essential for determining the efficacy of new, experimental treatments for 
PD.[87] Investigations into gait disturbance related to PD have primarily examined the 
spatiotemporal, kinematic, or kinetic parameters of gait. Advantages to objectively and 
quantitatively analyzing gait disturbances using technical devices is the focus on the cardinal 
motor symptoms of the disease (bradykinesia, rigidity, tremor and postural instability) associated 
with PD.[88] Technologies that have been developed and tested for analyzing gait biomechanics 
in a laboratory setting primarily include timed tests, wearable data recorders, vision-based 
motion capture systems, force plates, electromagnetic systems, and pressure sensitive electronic 
walkways.[28, 87, 89]  Thus, several alternatives exist for quantifiably assessing study 
participant’s gait impairment and variability in a clinical setting. For this particular study’s 
interest conducting a clinical trial for testing the effects of Qigong exercise in PD, it is of interest 
to examine and select a workable gait measuring system. 
Selection criteria: An ideal technology for assessing gait disturbance in PD would be non-
invasive and simple to use, provide scientifically sound data, and inexpensive. Nevertheless, 
many of the kinematic and spatiotemporal measuring systems available and used in a clinical 
setting for measuring gait in PD may be time-consuming, labor intensive in their set up, 
impractical, and even disrupt a person’s natural gait pattern.[87, 90] Based on characteristics of 
the different options available, criterion was developed to determine what system measuring gait 
parameters should be selected for a clinical trial testing the efficacy of Qigong exercise in 
Parkinson’s disease. Considerations for selecting a gait analysis system were categorized into 
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simplicity of testing, validity of relevant gait measures (scientific sound data), and practicality of 
system for the particular trial.   
With regard to simplicity of testing, ease with which study participants interface with the 
system, especially given the physical impairment associated with PD systems must be considered 
as well as reliable acquisition and storage of data during testing procedure.  Thus, duration of 
time and discomfort on part of the participant, and to a lower degree clinician, should be 
minimized.  This would further include selecting a system that would most easily be accessible 
for study participants with respect to location of laboratory.  A gait analysis system should also 
provide relevant, valid, and reliable gait parameters pertaining to measuring gait impairment and 
variability.  A system should accurately measure stride length, step length, and velocity, and the 
most prominent signs of gait impairment, with as well as indicators of postural instability: double 
support time and shifts in center of mass. [7, 27, 29] Preferably, a system would allow multiple 
cycles for testing during each phase of testing to both strengthen reliability of data and assess for 
variability in the gait parameters. Finally, practicality, related to simplicity of testing, is another 
consideration for selection of a spatiotemporal measurement system. Cost of the system as well 
as ease of setup, tear down, and storage of the technology is a determining factor.[91] Further, 
availability of laboratory space and time is another consideration as well as the convenience and 
available of a system already.  Further, the particular piece of technology would have been used 
ideally in previous studies in the laboratory measuring similar gait patterns in Parkinson’s 
disease to verify its reliability. 
Timed Up and Go test: The Timed Up and Go test has been used to assess motor disability 
in PD, where study participants are timed while doing a sequence of tasks: sit-to-stand, walking 
3 meters, turning, and stand-to-sit. The longer the duration of time to complete the tasks, the 
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greater the gait impairment indicated.[92] This test has been used in addition to applying mobile 
inertial sensors and a portable data-logger (Physilog®) while performing the TUG test, dubbed 
the iTUG test. On its own, the TUG test is easy for a clinician to set up and for a participant to 
perform, primarily only requiring the materials of a chair and stopwatch.  However, only one 
quantity is measured using this method: time.  In addition to human error (starting and stopping 
the watch), this method does not quantitatively and sensitively assess any gait and balance.  The 
additional sensors provided data for upper body (arm swing velocity, range of motion, and 
asymmetry), lower body (cadence, gait cycle time, stride velocity and length, variability of stride 
time and length) trunk (angular velocity and range of motion) turning (turning velocity) and sit-
to-stand (velocity) parameters.  While a combination of these parameters could be used to 
suggest generalized bradykinesia (arm swing, cadence and trunk rotation during gait, and turning 
velocity), a Matlab (Mathworks, Natick, MA) program separated and analyzed data from the 
sensors to provide the gait and postural measures. This method, however, did not sensitively 
assess gait variability, perhaps due to the short length of walking, but did allow for multiple 
cycles to be tested. While the cost of the sensors were not disclosed in study, iTUG may serve as 
a quick and easy way to evaluate both PD and possible therapeutic interventions.[93] 
Accelerometers: On their own, inertial sensors in the form of wearable accelerometer-
based motion detectors may also be used to measure relevant features of posture, balance, and 
gait.[94]  By measuring acceleration and the direction, frequency, and intensity of movement, 
velocity, displacement, and stride length can be derived as well as when a subject walks with the 
device attached to their sternum, lower back, or waist. [90, 94] In addition to acceleration sensor 
applications on ‘smart’ devices such as phones or watches, the quarter-sized, wearable FitBit Zip 
(FitBit Inc., San Francisco, California) counts steps and measures stride length. [90]  Wearable 
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accelerometers tend to be cheaper and less cumbersome than other gait measuring technology as 
well as more widely available. [90, 95] Kinematic data can either be logged and/or wirelessly 
transmitted, making recording data suitable for research purposes.[95]  Given these advantages, 
wearable accelerometers may be applied to evaluate the change in motor symptoms of persons 
with PD over a longer period of time.[90] While this technology may be suited for gathering 
longitudinal data, it does not gather more than a few parameters (stride length and velocity) 
related to assessing gait impairment and variability.  Given the relatively short period that the 
prospective trial will be run (6 weeks) with the pre-/post design, wearable accelerometers may be 
a useful technology, but in a future trial assessing the validity of a therapy for PD. 
Vision-based gait analysis: Vision-based gait analysis, primarily relying on 2-D 
representations captured using videos have been used in previous decades to assess and describe 
markers of gait.[91] By recording a subject participant performing a walking task either in a 
single or multiple perspectives, 3-D body structures, limbs, and their kinematics can be modeled 
based on the 2-D projections captured in the image sequence.  Body structures on consecutive 
frames are thus analyzed, yielding position and velocity values.[96] As opposed to “active 
sensing” (ie. sensory devices attached to study participant’s body), the “passive sensing” of 
video-based gait analysis relies on more natural signals (in this case, light wavelengths from 
unencumbered body) for a touch free experience. This feature is particularly advantageous 
compared to active sensing systems, where wearable devices may prove to be inconvenient, 
intrusive, or even impossible to apply for study participants. The off-line analysis of video 
heavily relies on making assumptions about the initial stance and physiology of the participant 
and as well as often probabilistic motion models (ie. the Kalman filter) offset background clutter 
and complex dynamics that may interfere with proper analysis.[97] The application of motion-
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models and additional camera perspectives (sometimes study participants may escape view 
during testing) can also be used to improve the overall quality and reliability of collected data, 
and with algorithms, develop a 3-D limb tracking system.[97, 98] Even still, the complexity and 
validity of data analysis as well as the expertise required to adequately employ these methods is a 
drawback for this method.  Light markers can be used to enhance the accuracy of this system, but 
occlusion (the marker signal leaving camera range) is the greatest limitation of this system. 
While additional cameras can be included to offset occlusion, this adds extra costs to the system.  
Nevertheless, given how active markers emitting light, the light makers’ strobe can be uniquely 
identified by the system, serving as an advantage over passive systems. Even still, light markers 
work wirelessly, requiring added electronics, batteries, and thus increased weight on the 
participant and complexity to the system.[98] 
Pilot study gait analysis: In a pilot study examining the effects of Qigong exercise on 
persons with Parkinson’s disease using a pre-/post-intervention, single group design, the Vicon 
512 (Vicon Peak, Lake Forest, CA) video motion capture system was used (a form of vision-
based gait analysis), which included 16 markers on the patient and six cameras.[83] The system 
was used to measure patients’ gait performing both a straight-line task (walking 10 meters) 
turning task (walking through a doorframe) using early and late cues for a total of 12 trials, three 
trials for each combination.  Using Matlab programming, trajectory and video data was 
computed to find each subject’s spatiotemporal parameters of stride time, stride length, double 
support time, gait velocity, and gait variability.  
Using this video motion capture system, multiple gait cycles were able to be tested 
allowing for more data collection and the assessment of gait variability in subjects.  The standard 
markers for gait impairment in PD (stride time, stride length, double support time, gait velocity) 
36 
	
were able to be assessed using this system using a visual cue in multiple conditions: straight line 
as well as turning tasks, thus giving indication of a patient’s gait pattern in multiple different 
scenarios.  
Even still, the use of this system was not without its challenges.  The collected raw 
trajectory data and video recordings required filtering and the development of specific Matlab 
programming. Further, in order to find most of the gait parameters, a foot center point was 
extrapolated using the foot-velocity algorithm method using other markers on the subject.  For 
the testing, sixteen retro-reflective markers were attached to the study participant’s lower body, 
which measured the position of their sacrum, anterior superior iliac spine, thigh, knee, tibia, 
ankle, heel and second metatarsal head.  Both putting on this gear and performing all twelve 
trials is time-consuming and could prove to be difficult for persons who have pre-existing 
walking and balance problems, despite the Vicon system being the gold standard for gait 
assessment.[99] Yet in addition to measuring the kinematic parameters of stride and step length, 
stride time, cadence, velocity, and single/double support time, the Vicon system has also been 
verified to reliably assess joint angle curves, another indicator of gait impairment in PD.[100] 
Further, motion capture systems such as the Vicon are expensive and require complex set up and 
a particular lab environmental setting for use.[91]  
  Force plates: Force plates may be another technology used to assess gait variability and 
postural instability, also indicating for risk for falling in PD. [91] The trajectory of a study 
participant’s center of pressure for a patient can indicate amount of sway. However, the use of 
force plates may be limited, especially given that not all are portable devices.[91, 101] Using the 
ground reaction force measured when the forefront is solely in contact with the force plate while 
walking across the force plate, a study participant’s gait variability can be calculated using the 
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“ground reaction vector technique.” The portability of a system is an asset, requiring less set up 
time and available laboratory space. While the system may reasonably provide gait variability 
data and can process multiple cycles, portable force plates may not provide as accurate results as 
the Vicon system. Further, force plates generally do not capture other measures of gait 
impairment (velocity, step and stride time, etc.). Therefore, the use of force plates may best be 
used as supplement to other gait parameter measuring systems as well as for non-clinical 
application.[101] 
Electromagnetic tracking systems: Electromagnetic systems, most 
notably Liberty (Polhemus, Colchester, VT), and Flock of Birds (Ascension Tech. Corp., 
Burlington, VT) as well as their variants rely on low-frequency electromagnetic  transmitter that 
detect sensors that are attached to segments of participant’s body.[95, 102, 103] The 
electromagnetic coil transmitter determines the position and orientation of the sensors in relation 
to itself based on fluctuations in the magnetic field, creating changes in signal amplitude.  For a 
trial, data is collected and transmitted to a computer while moved their hands and forearms, 
where it is analyzed offline using a Matlab program to assess severity and type of tremor (for 
PD) based on oscillations in sensor position.[103] However, the system can detect up to six 
degrees of motion (rotational and translational) and the displacement data can be verified easily 
by placing the sensor at a pre-measured distance away from the electromagnetic 
transmitter.[103] While nearby metallic objects may affect sensor data, this system collects and 
displays accurate data that is comprehendible in real-time based on wave amplitude.[95, 103]  
The cabling between sensors may be uncomfortable and inhibit movement of a study participant. 
[102] Nevertheless, the high expense, lack of availability, and available laboratory space may 
prohibit the use of this assessment tool for measuring kinematic and spatiotemporal parameters 
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in the current study.[102]  Further, while the electromagnetic system may be an effective tool for 
assessing tremor severity, other technologies may better assess parameters more suited to gait 
impairment and variability in PD, which is the primary interest in this study.[95, 103] 
Electronic, pressure sensitive walkways: Electronic walkways may also be a viable tool 
for measuring gait parameters in the prospective study, where the most popular systems are the 
GAITrite (CIR Systems Inc., Franklin, NJ) and the Gaitmat II (EQ Inc., Chalfont, PA). The 
GAITrite system is a 16 foot (4.9 meter) long walkway that relies on pressure sensitive pads that 
is analyzed by an on-board processor and transfers gait parameters (velocity, step time and stride 
for each foot) to a computer with application software.[99, 104] Similarly, the Gaitmat II is a 
four meter long walkway has been employed in previous studies, which digitally records, 
processes, and immediately displays a study participant’s gait velocity, step length, double 
support time, and step variability.[105]   
However a clinical walkway is limited in that it does not test gait in the complex 
environment in which a typical participant must function and only assesses measures pertaining 
to the lower body.[87, 89]  While walkways may also be bulky and expensive, they do provide 
immediate, automatic analysis of a participant’s gait pattern and can used for multiple 
cycles.[87] Given that the Gaitmat II has been demonstrated straightforward to use in a clinical 
setting and measures these parameters directly related to gait variability, including hypokinesia, 
this system may be a promising in terms of quantitatively assessing gait severity in PD.[28, 105]  
Selection of gait analysis technology for study: Based on the criterion developed and an 
examination of possible technologies available for assessing gait pattern for the current, the 
electronic walkway, specifically the Gaitmat II, was selected.  As a passive sensor system, the 
walkway is simple for study participants to use as any wearable sensors are dispensed that may 
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be haphazard or inconvenient; all they must do is walk a short distance of seven meters total (two 
meters prior to, four meters on the walkway, and two meters before stopping) for five cycles 
total.  The system also provides immediate, displayable and storable data on the relevant gait 
measures after each cycle.  Thus, the clinician can recognize any possible abnormalities at the 
time of testing, and the data can be stored for later, offline analysis.  
Although the gold standard Vicon system was used in a previous study testing the same 
form of Qigong exercise in PD, this system may not be necessary to use in this pilot study, 
especially when considering the comparable simplicity of the Gaitmat system.  The Gaitmat II 
provides sufficient baseline quantifiable gait parameters during a standard straight-line walking 
task that can be compared in the two group, pre-post-intervention design. The current study is 
small and is investigating the feasibility of the intervention in PD. If the study findings warrants 
further investigation of the effects of the therapy in PD on gait pattern, perhaps the Vicon system 
or even wearable accelerometers can be used to gather more information regarding performing 
more complex tasks in a future, larger, or even longer study.  
Conveniently, a Gaitmat II system used in prior investigations of PD was also available 
for use in the laboratory near the clinician’s office who will perform the UPDRS on each 
participant. The device can be conveniently stored in the laboratory, and requires little to no 
setup for each use.  Given that the Gaitmat II system is borrowed, no additional cost is required 
of the study. Thus for the above reasons, the Gaitmat II system is the technology of choice for 
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Chapter 2: A Portrait of Anxiety and Depression in the PD Population 
Abstract 
Parkinson’s disease is a neurodegenerative condition traditionally characterized by progressively 
severe motor symptoms. Recently, the disease’s non-motor symptoms, specifically anxiety and 
depression have received greater attention for contributing to impaired quality of life in PD.  This 
study aims to elucidate the prevalence and relationship of these mood disorders as they relate to 
each other and other aspects of the disease. We hypothesized that relevant anxiety or depression 
symptoms would be reported in 50% of the PD population, and that severity of these symptoms 
would increase with respect to overall disease severity.  
One thousand two hundred twenty one patients diagnosed with PD were systematically 
evaluated at a clinic for overall disease severity, anxiety and depression symptoms, and motor 
impairment. Twenty five percent of the sample population were receiving their first diagnosis of 
PD.  Medical records were stored in a database and retrospectively analyzed.  Sixty six percent 
of the sample population was found to have anxiety symptoms, while 51% was found to have 
mild to severe depression symptoms.  These findings fall within previous estimates, though 
much disparity exists in these past studies. The rate of co-morbidity between these symptoms of 
45% was higher than previously reported. The rate of anxiolytic use was 18% and 31% for 
antidepressant use, with 9% of the population prescribed both forms of medication. Of those 
prescribed medication for mood disorders, higher rates of anxiety and depression were reported, 
suggesting the efficacy of these medications may be limited. 
While mood symptoms tended to worsen with overall disease severity, the study confirms 
previous findings suggesting the progression of serotonergic degeneration, attributed to mood 
disorders, is nonlinear with respect to worsening of PD.   Further, findings of the study support 
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previous claims that a lack of consistent methods for identifying and treating mood symptoms in 
PD remains an issue in managing the disease.   Thus, the study suggests anxiety and depression 
are relevant non-motor symptoms of PD, and more consistent tools are required for properly 























While Parkinson’s disease (PD) has been traditionally associated with cardinal motor 
features of bradykinesia, tremor, rigidity and postural instability, its non-motor symptoms (NMS) 
oftentimes affect quality of life more negatively than motor symptoms, contributing up to 60% of 
the decline in a patient’s quality of life.[1-5] Anxiety and depression, two primary NMS in PD 
are associated with greater motor and cognitive impairment as well as sleep problems, social 
phobia, and apathy.[6, 7]  Mood symptoms are often considered the result of multiple neuronal 
degenerations and attributed to similar noradrenergic, serotoninergic and dopaminergic 
malfunction associated with PD.[7-9] Additionally, genetic factors have been linked to the 
pathogenesis of anxiety in PD.[10] 
Studies examining the prevalence of anxiety and depression in patients with PD show 
wide disparity in diagnosis criteria, sample sizes, and estimated frequencies. [10-17] Past studies 
estimate 5% to 69% of the PD population suffers from anxiety. [10, 18-20] Generalized anxiety 
disorder, social phobia, panic disorder, and agoraphobia are the most common anxiety disorders 
found in PD.[20, 21] Depression in PD has been estimated to affect between 2.7% and 90% of 
patients depending on the study. [7, 18, 20]  The frequency of major depression has been 
reported in 5% to 20% of the PD population while minor forms of depression affect an additional 
10 to 30% of patients.[9] While variations in severity and frequency may be partially due to 
different diagnostic tools used in various studies, depression is considered uniformly under 
diagnosed.[7, 22] More studies examining the rate and severity of anxiety and depression 
symptoms in PD are needed. 
Findings detailing the overlap between anxiety, depression, and disease progression in 
patients with PD remain inconclusive. The overlap rate between depression and anxiety in PD 
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could be quite high.[8] For example, 67% of those with depression had also an anxiety disorder 
while 92% of those with an anxiety disorder had co-morbid depression.[23] It has been reported 
that between 14% and 26% of PD patients suffer from both anxiety and depression.[23-25] 
Variations in past estimates of co-morbidity of these mood disorders in PD were attributed 
partially to the differing in diagnostic criteria.[25, 26]  More severe anxiety and depression in 
individuals with PD often seem to accompany greater motor impairment, however, the PD stages 
measured by Hoehn and Yahr (HY) scale have been found not to correlate with the worsening of 
mood symptoms.[10, 19]  Furthermore, disease duration had not been shown to correlate with 
anxiety symptoms, except that younger age of disease onset was associated with higher 
anxiety.[25] While anxiety and depression were thought to predate motor symptoms, past studies 
of mood disorders in the early stage of PD remain rare. [28,14] In general, there has been a lack 
of clarity in understanding the overlap between anxiety and depression and the relationship 
between disease duration/severity and mood symptoms.   
A better understanding of the characteristics of mood disorders in individuals with PD 
may help to develop appropriate diagnosis tools and therapies for mood disorders in PD. The 
current study aims to examine the prevalence, severity, and relationship of anxiety and 
depression with PD disease progression. We expect to find a statistically significant correlation 








Patient Evaluation: A retrospective analysis of records from 1221 individuals diagnosed 
with idiopathic PD was performed in the current study. All patients were evaluated by the same 
physician specialized in patient care for PD during the patient’s first visit to the Parkinson’s 
Disease and Movement Disorder Center at the University of Kansas Medical Center. Diagnoses 
were made using the United Kingdom Parkinson’s Disease Society Brain Bank Criteria.[27] 
Patients included in the study were determined to have PD with a confidence level of 90-100%.  
Any patient who did not meet the diagnostic criteria or complete requisite questionnaires and/or 
assessments was excluded. De-identified patient examination information was stored in a secured 
database.  
Prevalence of Anxiety and Depression: Severity of anxiety and depression symptoms was 
evaluated using the Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI). [28, 
29] BAI scores were classified by level of severity based on the scale criteria: minimal anxiety (0 
- 7), mild anxiety (8 – 15), moderate anxiety (16 - 25), and severe anxiety (26 - 63).  The same 
was done for BDI scores: minimal depression (0 - 9), mild depression (10 - 18), moderate 
depression (19 - 29), and severe depression (30 - 63). In the current study, mild to severe levels 
of anxiety and depression were considered clinically relevant.  Patient scoring in mild to severe 
levels on both the BAI and BDI were considered to have co-morbid anxiety and depression 
symptoms.   
Disease duration, severity, and use of medicine for anxiety/depression: Age and date of 
both initial PD symptom onset and subsequent diagnosis were recorded. Based on disease 
duration, subjects were divided into four categories as newly diagnosed (disease duration 0 
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years), early (1–5 years), established (6–10 years) and advanced (more than 10 years).[30]  
Disease severity was assessed using the Unified Parkinson’s Disease Rating Scale (UPDRS), 
which includes four sections, I-mentation, behavior and mood (MENTAL), II-activities of daily 
living (ADL), III-motor examination, IV- motor complications as well as Hoehn and Yahr (HY) 
staging of the condition and Schwab and England Activities of Daily Living Scale (SE). [31, 32] 
The UPDRS score was found by totaling all five sections.  The MENTAL sub-section score, 
which includes a question about depression was also used to measure mood.[33] HY stage was 
used to assess disease severity. ADL and MOTOR sub-scores were used to determine functional 
impairment and motor disability, respectively.  Prescribed medication and dosages of anti-
depressants and/or anti-anxiolytics along with Mini Mental State Exam (MMSE) scores were 
also gathered, (Table 2-1). [34]  
Relationship between Anxiety, Depression, and Disease Duration/Severity: Strength of 
relationships between mood symptoms, disease duration, and disease severity were determined 
by correlating the sample’s disease duration, UPDRS scores, and HY stage with BAI and BDI 
scores using a Pearson Correlation Coefficient ( r ). Strength of correlation coefficient was 
interpreted using Munro’s descriptive range in terms of ‘little, if any’ (.00 - .25), ‘low’ (.26 - .49) 
‘moderate’ (.50 - .69), ‘high’ (.70 - .89) and ‘very high’ (.90 – 1.00) correlation values.[35]  
Furthermore, subjects were divided into sub-groups based on HY stage and range of 
disease duration. For each HY stage or disease duration sub-group, the number and percentage of 
subjects as categorized by their anxiety and depression levels were reported. Chi-squared tests 
were used to analyze significant difference between level of mood symptom severity with 
respect to disease duration or motor severity. The alpha value less than .05 was considered 




The data revealed that around 66% of the sample population experienced clinically 
relevant anxiety symptoms with 34%, 20%, and 11% experiencing mild, moderate, and severe 
levels of anxiety, respectfully (Table 1). About 49 percent of the sample experienced relevant 
depression symptoms, with 33%, 12%, and 3% experiencing mild, moderate, and severe levels of 
depression, respectively. Approximately 45% of the sample experienced clinically relevant 
symptoms of both anxiety (BAI score range of 8 – 63) and depression (BDI score range of 10 – 
63).  The relevant anxiety symptoms were reported in 92% of individuals who also report 
relevant depression symptoms. About 70% of the sample population reported either relevant 
anxiety, depression, or both mood symptoms. 
About 18% of the sample’s population were prescribed anxiolytics (diazepam, 
clonazepam, lorazepam, or alprazolam) and 31% prescribed antidepressants (primarily any drug 
classified as selective serotonin reuptake inhibitor) (Table 2). The overlap between users of the 
two types of medicines was 9% of the sample’s population. Of persons prescribed anxiolytics, 
83% still reported relevant anxiety symptoms with distribution rates of for mild, moderate, and 
severe anxiety, respectively. Of those prescribed antidepressants, 74% still reported relevant 
depression symptoms with distribution rates of for mild, moderate, and severe anxiety, 
respectively. 
Disease duration showed little if any correlation with BAI score (r = .19) and low 
correlation with BDI score (r = .28) (Table 3). Disease severity (UPDRS score) showed 
significantly moderate correlation with depression (r = .51) and low correlation with anxiety (r = 
.44) scores, respectively. Similarly, HY stage showed low but significant correlation with anxiety 
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(r = .40) and depression (r = .30). BAI and BDI scores were moderately correlated (r = .69). A 
high correlation was found between UPDRS score and HY stage (r = .78). Both UPDRS score 
and HY stage were moderately correlated with disease duration (r = .52 and .58, respectively).   
When grouping the sample by the level of anxiety severity, Chi-squared tests revealed 
that the ratio of patients with moderate (p=.008) or severe (p<.001) level of anxiety increased 
significantly as disease duration increased (Figure 1). The ratio of subjects with mild level of 
anxiety remained relatively constant (p=.880), while the ratio of subjects with no obvious anxiety 
symptoms significantly decreased (p<.001) across the disease duration. Similarly, the ratio of 
subjects with moderate levels of depression significantly increased (p<0.008) with respect to 
longer range of disease duration (Figure 2). A significant decrease (p=.0009) in the ratio of 
patients with no obvious depression symptoms was also found across the disease duration axis. 
No significant correlation was found in patients with mild or severe levels of depression with 
respect to disease duration.   
The ratio of patients with moderate or severe level of anxiety increased significantly 
(p<0.05) with increased disease severity as measured by HY stage (Figure 3). No significant 
change was found in the percentage of patients with mild anxiety level with respect to HY stage. 
However, the percentage of patients with no obvious anxiety symptoms significantly decreased 
across the HY stage axis. Similar findings were observed for depression levels with respect to 
HY stage (Figure 4). 
Discussion 
Results of the current study regarding prevalence of mood symptoms generally agreed 
with past studies. We found 70% of sample population experienced relevant mood symptoms, 
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where the rate of anxiety symptoms was found to be 66% while the rate of depression symptoms 
of 49%. Both rates fall in the middle to upper end of previously estimated range of rates for 
anxiety (5% to 69%) and depression (2.7% to 90%).[7, 10, 18-20] The prevalence of mild 
depression (33%) suggest more PD patients suffer from sub-clinical forms of depression than 
previously estimated.[9] The prevalence of major depression in the PD population (15% at 
moderate and severe levels) falls within previous estimates (5% to 20%).[9] A meta-analysis of 
past 14 studies concluded 46% of PD patients suffer from depression, while another analysis 
postulated a deficit in prognostic tools that inhibited an accurate measurement of depression in 
PD.[15, 16]  A review of 51 studies reported 17% of PD patients suffer from major depression 
and 22% suffer from minor depression.[17] Furthermore, we have observed a moderate level of 
correlation (r = 0.69) between anxiety and depression. The overlap rate of 45% in our sample 
were higher than the previously estimated range of 14% to 26%.  [23-25] While most of past 
studies used small sample sizes as well as a variety of study sites and metrics, the current study 
analyzed data from a specialized PD clinical center with a large sample size (n=1221). Each 
subject was administered using a standard examination of their motor and non-motor PD 
symptoms by the same neurologist, resulting in valid within-rater reliability.   
Compared to a few past studies involving large samples, the current study gathered more 
reliable data that allowed a quantitative assessment of levels of anxiety and depression in our 
sample. The largest number of subjects previously reported in a study examining anxiety and 
depression in 1307 PD patients.[11] More than half (56%) exhibited symptoms of anxiety and 
more than 22% were found to suffer from depression, as assessed by the anxiety and depression 
section of the Non-Motor Questionnaire for PD (NMSQuest).[12]  Another study used the same 
tool in examining 525 PD patients in the UK, USA, Germany, Israel, Japan, and Italy.[14] They 
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reported that 48% of PD patients experienced anxiety or depression. The NMSQuest relies on 
two questions about mood symptoms and does not distinguish different levels.[13]   A major 
strength of the current study was that the same physician conducted assessments for all patients 
involved, while past studies relied on multiple clinics, doctors, and differing diagnostic tools for 
assessing mood symptoms in their sample populations. More importantly, the use of Beck 
criteria for mood symptom allowed us to distinguish individuals with mild, moderate, or severe 
mood symptoms.  
The large variation reported in the literature in terms of prevalence of mood symptoms in 
patients with PD suggests an overall difficulty in recognizing mood symptoms in PD.   Anxiety 
and depression in PD is thought to be atypical when compared to mood disorders in the general 
elderly population, reflecting both the physiological and psychological components of PD.[8, 22] 
However, evidence supporting a distinction between PD and non-PD depression has been 
inconsistent.[9] Depression in PD has been characterized as predominantly manifesting somatic 
features such as loss of energy or psychomotor slowing.[36] These and other common features of 
depression such as altered sleep and appetite, reduced memory, or weight change can overlap 
with PD symptoms that makes depression difficult to be diagnosed in PD populations, even for 
an experienced clinician.[36, 37] 
Our findings of the rates of use of anxiolytics and antidepressants for treating mood 
symptoms in PD are consistent with previous estimates,[4, 38] however, our data further 
suggested that the mood symptoms in PD are generally under-treated and the effect of current 
pharmacological treatments is limited. First, only a portion of patients with mood symptoms take 
those pharmacological medicines. In the case of the current study, only 18% of the sample 
population took anxiolytics while 66% of the sample population were found to have anxiety 
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symptoms as measured by Beck Anxiety Inventory. For depression, 31% of the sample 
population took anti-depressants while 49% reported depression symptoms. While the current 
study did not account for non-pharmacological treatment, the findings, along with other reports 
in the literature, have suggested that anxiety and depression in PD is undertreated.[7, 22] Second, 
more than three-fourths of individuals prescribed a form of those medications still reported 
relevant mood symptoms ranging from mild to severe. Finally, it is unknown to what extent 
those medications have helped the individuals with mood symptoms in the current study, 
however, our data suggested only a limited effect.  All rates of relevant anxiety or depression 
(mild to severe levels) were higher in the sub-group of patients prescribed medications for 
treating mood symptoms compared to those without such a prescription (Table 3). For instance, 
severe anxiety symptoms were reported in 18% of those with anxiolytics but 10% without. 
Therefore, the use of these medications did not treat the symptoms to a comparative level as 
those without subscription.  
Two hypotheses have emerged regarding the cause of depression and anxiety in PD.  One 
theory considers the altered mood as a reactive state to the perceived social and motor disabilities 
inherent to PD.[10, 19] The other theory suggests that the mood symptoms are intrinsic to the 
disease, based on the observation that the onset of mood symptoms in some PD patients occurred 
prior to motor symptoms.[19, 21] Further, dopamine depletion has been associated with anxiety 
and depression in PD, suggesting mood symptoms are either interrelated to motor dysfunction or 
one of the earliest signs of PD.[9, 10, 39]  An anxious personality is even considered to be a risk 
factor for developing and progression of PD,[40] and evidence suggests mood alteration 
influences severity of motor symptoms.[41]  Given the complexity of mood issue and limited 
effect of the current pharmacological treatments, future research may need to help the 
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development of non-pharmacological interventions that may provide a holistic benefits to 
patients with PD and mood symptoms. 
In the current study we examined possible associations between mood symptoms and 
disease duration or disease stage and have some interesting findings. As expected, our data 
showed a high correlation between UPDRS score and HY stage, moderate correlations between 
BAI and BDI scores, between, and between disease duration and UPDRS score or HY stage. 
However, mood symptoms were only mildly correlated with disease duration or HY stage. 
Although dopaminergic denervation occurring may be associated with mood symptoms, 
disturbances in the serotonergic and noradrenergic system more closely relate to the 
manifestation of mood symptoms.[7] While damage to the serotonergic system is shown to 
increase as the disease progresses, this progression is thought to be non-linear and vary between 
patients with respect to disease duration.[42] The non-linear progression of serotonergic 
degeneration in PD may very well explain the findings of the current study.[30, 42]  When 
grouping the sample by the severity level of anxiety or depression, we observed a clear pattern: 
the rate of individuals with moderate or severe mood symptoms significantly increased over 
disease duration, while the rate of individuals without mood symptoms significantly decreased. 
Similar findings were observed for HY stage too. Put together, it seemed that occurrence rate of 
mood symptoms in PD patients increase with either disease duration or disease stage, but may be 
not show a strong linear pattern.    
Limitations: Several factors limit the implications of the study findings. The sample population 
may not fully represent the whole PD population given that it only consists of individuals able 
and willing to be examined at a clinic in an urban setting.  Due to the cross-sectional design, no 
causal link can be established between the onset of anxiety and depression symptoms and the 
58 
	
development of PD symptoms. Additionally, how mood disorders develop or change as the 
disease progresses remains unknown.   While the current study suggested mood disorders were 
prevalent in the PD population, little remains clear on how best to recognize and treat these 
symptoms in PD. 
Conclusions: The current study examines the prevalence of anxiety and depression symptoms in 
a large sample group of patients diagnosed with PD.  The uniform use of the Beck criteria in 
assessing mood symptoms allowed for direct with-in group comparison of symptoms as well as 
elucidating the severity level of anxiety and depression.  Results of the current study confirmed 
previous findings that anxiety and depression are relevant non-motor symptoms, where an 
average of 2 out of every 3 individuals with PD are affected by anxiety and half of patients with 
PD suffer from depression. In general, about 70% of the sample population reported one or both 
mood disorders. While these symptoms may worsen as the disease progresses, findings suggest 
the progression is non-linear. We hypothesized that mood symptom and disease progression 
would be significantly correlated, and while a relationship between mood symptoms and overall 
disease severity was found, it was only a mild correlation.  However, analyses of occurrence 
rates of mood symptoms by grouping the sample population by severity level revealed clear 
pattern of the increase in mood symptoms as either the increase in disease duration or disease 
stage. Such result was a unique finding of the current study. The other strength of the current 
study may include the use of uniform diagnostic tools which might improve the clinical 
assessment of mood disorders in PD. Further study is needed in discerning the relationship 
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Table 2-1 Sample Characteristics 
Mean and standard deviation characteristics of the sample population. Percentages of the total 
sample population are given for prevalence of subjects included in each sub-group level of the 
BAI and BDI scales. 
Population n=1221 BAI score 12.9 (9.6) 
Gender 
(Male/Female) 62% 38% BAI 0 - 7 34% 
Age (years) 67.2 10.8 BAI 8 - 15 34% 
Onset Age (years) 61.9 11.1 BAI 16 - 25 20% 
Onset age < 61 
(years) 45% BAI 26 - 63 11% 
Disease Duration 
(years) 5.3 (5.9) BDI score 10.9 (7.9) 
Symptom duration 
(years) 7.2 6.2 BDI 0 - 9 51% 




     BDI 19 - 29 12% 
UPDRS score 40.3 (15.8) BDI 30 - 63 3% 
MENTAL sub-score 2.5 2.0 HY Stage 2.2 (1.0) 
ADL sub-score 12.5 6.8 HY Stage 1 28% 
Motor sub-score 25.3 9.1 HY Stage           1.5 - 2 34% 
SE sub-score 80.3 12.5 HY Stage          2.5 - 3 26% 
MMSE score 27.6 2.9 HY Stage                3.5 - 4 8% 






Table 3 Correlation Values 
Pearson Correlation Coefficients (r values) are given assessing the strength of relationship 
between subjects’ assessed scores and characteristics of the sample population related to mood, 
disease progression, and PD disability.  








duration 0.281 0.192 0.576 0.522 
UPDRS 
score 0.508 0.438 0.782   
HY 
Stage 0.301 0.396  	
BAI 























Table 2 Anxiety level with respect to medication usage 
Subjects are classified by both their reported usage of anxiolytic and antidepressant medication 
usage and the average BAI score as well as prevalence of each level of anxiety are given per 
group. 
  Anxiolytic medication 
 
Antidepressant medication 
Prescribed Yes No Prescribed Yes No 
Prevalence 18% 82% Prevalence 31% 69% 
BAI score 17.0 (10.3) 12.1 (9.3) BDI score 15.5 (10.0) 11.8 (9.3) 
Rate 
(BAI 0 – 7) 17% 38% 
Rate 
(BDI 0 – 9) 26% 47% 
Rate 
(BAI 8 – 15) 35% 34% 
Rate 
(BDI 10 – 18) 51% 42% 
Rate 
(BAI 16 – 25) 30% 18% 
Rate 
(BDI 19 – 29) 19% 10% 
Rate 
(BAI 26 – 63) 18% 10% 
Rate 


















Figure 1 Anxiety prevalence with respect to disease duration 
Categorized by ranges of disease duration (DxD, years since initial diagnosis of PD), the 
prevalence of subjects included in each sub-group level of the BAI scale is given. The four 
categories of DxD consist of newly diagnosed (disease duration 0 years), early (1–5 years), 
established (6–10 years) and advanced (more than 10 years), while BAI sub-group levels consist 
of minimal anxiety (0 - 7), mild anxiety (8 – 15), moderate anxiety (16 - 25), and severe anxiety 

















Figure 2 Depression prevalence with respect to disease duration 
Categorized by ranges of disease duration (DxD, years since initial diagnosis of PD), the 
prevalence of subjects included in each sub-group level of the BDI scale is given. The four 
categories of DxD consist of newly diagnosed (disease duration 0 years), early (1–5 years), 
established (6–10 years) and advanced (more than 10 years), while BDI sub-group levels consist 
of minimal depression (0 - 9), mild depression (10 - 18), moderate depression (19 - 29), and 

















Figure 3 HY Stage with respect to anxiety prevalence  
Categorized by HY stage (disease severity), the prevalence of subjects included in each sub-
group level of the BAI scale is given. HY stage range is from 1 to 5, with more advanced stage 
indicating more severe disease impairment and disability. BAI sub-group levels consist of 


















Figure 4 HY stage with respect to depression prevalence  
Categorized by HY stage (disease severity), the prevalence of subjects included in each sub-
group level of the BDI scale is given. HY stage range is from 1 to 5, with more advanced stage 
indicating more severe disease impairment and disability. BDI sub-group levels consist of 
minimal depression (0 - 9), mild depression (10 - 18), moderate depression (19 - 29), and severe 















Chapter 3: A randomized pilot trial of Qigong exercise in PD 
Abstract 
While Parkinson’s disease (PD) is commonly understood to consist of motor symptoms, non-
motor symptom (NMS) features are receiving greater attention.  Impaired sleep quality in 
particular affects many persons with PD, and can significantly affect quality of life.  Previous 
findings have suggested Qigong meditation exercise may improve NMS, specifically sleep 
problems, as well as gait and balance issues. While standard care of PD may improve motor 
symptoms, alternative therapies such as Qigong meditation exercise may provide complementary 
benefits for treating NMS as well.  This study’s aim is to determine the efficacy of Qigong 
meditation exercise on improving sleep quality in PD as well its benefits on NMS and gait 
pattern. Using a randomized controlled trial, the 16 study participants with PD who completed 
the study were randomly assigned to either an experimental group practicing Qigong exercise or 
a control group practicing sham Qigong exercise. Each group consisted of 8 participants, and 
study participants practiced their respective exercise twice daily for a six week trial period.  Pre- 
and post-intervention testing was performed to assess sleep quality, fatigue, thinking abilities, 
mood, as well as gait impairment.  Standard clinical assessments specific to PD were used to 
assess sleep quality and disease severity, while gait impairment was assessed using a Gaitmat II 
system.  Results suggest patients’ sleep quality significantly improved in the experimental group, 
while improvement in fatigue approached significance.  Gait performance improved in both 
experimental and control groups with no significant difference between the groups.  Our results 
confirm previous findings that Qigong exercise may provide persons with PD sleep quality 
benefits, but that a history of mood symptoms may limit the efficacy of the exercise.  Further, 
regular mild exercise, regardless of breathing techniques unique to Qigong, may improve gait 
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functioning.  Additional studies with longer study duration and increased sample size are 





















In recent years, non-motor symptoms (NMS) of Parkinson’s disease (PD) have received 
increased attention.[1, 2] NMS in PD contribute to disability and shorten life expectancy, and 
may affect quality of life more significantly than motor symptoms.[1, 3] NMS in PD include 
sleep dysfunction, autonomic dysfunction, mood disorders (anxiety and depression), cognitive 
impairment/dementia, and sensory symptoms.[2, 4-6] Up to 88% of persons diagnosed with PD 
may suffer from one or more NMS.[7] Those symptoms become increasingly prevalent 
throughout the course of the disease and may even precede the onset of motor symptoms by a 
number of years.[2, 8, 9].  Sleep dysfunction is a major NMS affecting up to 98% of individuals 
with PD and contributing significantly to decreased quality of life.[3, 8, 13] Sleep problems in 
PD include daytime sleepiness, insomnia, nighttime waking, restless leg syndrome (RLS), vivid 
and/or violent dreams, REM sleep behavior disorder, sleep apnea, and periodic limb movements 
during sleep (PLMS).[2-5, 8, 14] Fatigue is another prominent NMS in PD, characterized by 
tiredness, exhaustion, and lack of energy.[7] Up to one third of persons diagnosed with PD suffer 
from fatigue.[15] Cognitive impairment, ranging from mild to dementia, is the other prevalent 
neuropsychological symptom in PD patients. Further, anxiety and depression are also common 
NMS in PD and disrupt efficacy of PD treatments by significantly reducing rates of compliance 
for prescribed therapies. [10-12] 
NMS such as sleep dysfunction, fatigue, mood disorders, and cognitive impairment are 
not strongly related to dopaminergic pathways [6, 8] and are thus less responsive to available PD 
treatments targeting the dopaminergic pathways.[1] Alternative therapies may offer potential for 
improving sleep quality and other NMS in PD.[8]  Two forms of meditation therapy, Qigong and 
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Tai Chi that involve regulated breathing, slow movements, and meditation,[17] may improve 
sleep quality and overall energy in persons with PD.[18, 19] Qigong in particular showed 
promising results in improving balance, NMS especially sleep dysfunction, and quality of life in 
patients with PD.[17, 18, 20]   
In addition to improving NMS in PD, a few pilot studies indicate the benefits of Tai Chi 
and Qigong on gait and balance control in persons with PD.[18, 21, 38]  As a motor symptom, 
gait impairment in PD is common. Difficulties with gait in PD increases the risk of falling 
leading to injuries, loss of independence, and increased mortality.[22] Individuals with PD tend 
to walk with slower speed than healthy adults and take shorter but quicker strides that can result 
in tripping.[13, 22, 23] Decreased gait speed, step length, and stride length along with stooped 
posture characterize the gait impairment observed in PD.[22, 24] However, the potential benefits 
of Qigong remain unclear largely due to the lack of rigorous randomized trials.[20]     
The presence of anxiety and depression in persons in PD may limit the effect of anti-
parkinsonian therapy and other alternative therapies. Adherence to anti-parkinsonian therapy is 
often low in patients with PD who suffer also from anxiety or depression symptoms, which limits 
effects of the therapy and often associated with the overall worsening of PD symptoms.[11, 25]  
Individuals with PD and depression showed a lower average rate of compliance with a home-
based exercise program.[10] 
The current study is a randomized controlled pilot trial of a Qigong exercise in 
individuals with PD regarding outcomes related to sleep dysfunction, cognitive impairment, 
disease severity, fatigue, gait performance, anxiety and depression, and quality of life. In 
addition to examining outcome trends, we investigated issues related to study feasibility, 
especially possible influence of anxiety and depression on subjects’ compliance rates to the 
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interventions. We hypothesize the experimental group will show significant improvement in 
sleep and gait measures compared to the control, and that participants with mood symptoms will 
comply with the exercise at a comparatively lower rate. 
Methods 
Twenty-five patients with mild to moderate PD defined as Hoehn and Yahr (HY) stage 
between 1 and 3 were enrolled in the study. Prior to enrollment, individuals were screened for 
the following criteria: diagnosed with idiopathic PD; between 40 and 75 years of age, able to 
walk unassisted for 10 meters, no prior deep brain stimulation surgery, and no anticipated 
changes to PD medication within the study period. After signing an informed consent approved 
by the institutional review board, each participant was randomly assigned into either a control or 
experimental group by a computer-generated allocation number. The study participants and 
assessors were both blinded from the participant’s group membership. Participants in the 
experimental group learned the Qigong exercise while the control group learned a sham Qigong 
exercise.  
Each participant first went through the baseline assessment, which included the collection 
of basic medical history information, completion of subjective outcome questionnaires, and 
quantitative assessment of gait performance. During the evaluation, participants were asked to 
take their regular medication two hours prior to their evaluation in order to standardize results to 
a “practically defined on” state. Overall disease severity was evaluated by an experienced 
clinician using the Unified Parkinson’s Disease Rating Scale (UPDRS) including assessment of 
Hoehn and Yahr (HY) stage.[26, 27] Quality of life and NMS severity were assessed using the 
39-item Parkinson’s Disease Questionnaire (PDQ-39) and the 30-item Non-Motor Symptoms 
Questionnaire (NMS-Quest).[28, 29] Anxiety and depression were assessed using the 15-item 
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Geriatric Anxiety Scale and the 30-item Geriatric Depression Scale, respectively, which have 
both been validated to assess mood disorders in PD.[30, 31] Cognitive impairment was assessed 
using the Mini Mental State Exam (MMSE).[32] Executive functioning and task switching was 
evaluated using both the Frontal Assessment Battery (FAB) and the Trail Making Test with part 
A (TMT-A) and B (TMT-B) assessments.[33, 34] Fatigue was measured by the 16-item 
Parkinson Fatigue Scale (PFS).[35] The Parkinson’s Disease Sleep Scale 2 (PDSS-2) was 
administered to measure sleep quality, including motor symptoms at night, PD symptoms at 
night, and disturbed sleep. [8, 36]  
Gait testing was performed using the Gaitmat II (EQ Inc, Chalfont, PA), a computerized 
walkway 4 meters in length used to measure gait velocity, step length, double support time, and 
step variability.[37] To assess gait performance, participants stood one meter in front of the track 
and were given instructions to walk across the walkway at a normal walking pace.  The gait test 
was repeat five times for each participant to gather averaged walking velocity, stride length, step 
length, step time, swing time, stance time, and support time for both feet.  Student participants 
were tested with these battery of baseline assessments for motor and non-motor symptoms upon 
completing the six-week trial period as post-intervention testing. 
 After the pre-intervention baseline testing, two training sessions were held in the 
following two weeks, in which participants in each group learned and practiced the specific 
Qigong exercise (intervention) or Sham Qigong (control). Participants in the intervention group 
received two training sessions for the “six healing sounds” Qigong exercise from an experienced 
instructor. This mild exercise program was selected because it is easy to learn and practice, 
especially for those with limited physical ability. The Qigong exercise can be performed while 
standing, sitting, or lying down. If practiced properly, one session takes between 15 and 20 
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minutes. After two training sessions, participants were instructed to perform the exercise twice 
daily at home; once in the morning upon waking and a second time at night just before going to 
bed.  In addition to exercising at home, participants in this experimental group met once weekly 
for a group exercise session. This 45 to 60 minute session provided an opportunity for the 
instructor to observe and correct performance of the exercise, answer questions, and encourage 
group discussion of relevant issues related to both their PD symptoms or challenges related to 
practicing the exercise. To monitor compliance, participants maintained exercise diaries that 
were reviewed at weekly group sessions.   
The control group followed the same procedure, but learned a sham Qigong exercise 
instead. The physical movements of the sham Qigong exercise were identical, but involving no 
deep breathing, meditation, or uttering the sounds associated with the movements. Participants in 
the control group likewise kept a weekly exercise diary throughout the experimental period and 
turned them in during group sessions.  The weekly session similarly consisted of group exercise 
practice and discussion of relevant issues. Post-intervention assessment, which consisted of the 
same evaluations as in baseline assessment, was conducted on participants in both groups within 
two weeks after the end of the six-week intervention period.  
Independent t-test was used to compare the intervention and control groups on mean 
values of measured variables from baseline evaluation. Changes between pre- and post-
intervention scores were computed for all measured variables.  Changes in overall scores of 
PDSS-2 and UPDRS were compared between two groups using independent t-test. Changes in 
their sub-scores were analyzed using MANOVA for between group significance. The MANOVA 
was also used to compare the two groups on NMSS, GDS, GAS, TMT-A, TMT-B, MMSE, 
FAB, PFS, and PDQ-39, as well as on variables from gait performance measurements. In 
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addition to significance of results, we were equally interested in the trends shown in our results. 
For this reason, we conducted post-hoc analysis using independent t-test for between group 
differences on all data despite the results of MANOVA analysis. Data analysis included data 
from only participants with rate of compliance to daily home exercise sessions greater than 50% 
as measured by exercise diaries. The requested home exercise sessions include two daily sessions 
for six weeks.   
Results 
Baseline characteristics of age, disease duration, and symptom duration of the control and 
intervention groups were not significantly different (Table 3-1).  Nine participants did not 
complete the full study due to loss of interest (n=5), physical limitations (n=2), or scheduling 
difficulties (n=2).  Two participants, one from each group failed to meet the 50% home-exercise 
compliance criterion. Data from those who did not complete the study or failed the compliance 
criterion was excluded from analysis. No adverse effects resulted from the practice of the Qigong 
or sham Qigong exercise.  
Averaged rate of compliance of the study participants for the two sessions (am and pm) 
of daily home exercise ranged from 72% to 89% (Table 3-1). The relatively lower rate of 
compliance in the intervention group occurred primarily during the first two weeks of the trial 
period, which was only 43%. Some members in the intervention group reported difficulty in 
memorizing all components of the Qigong exercise and uncertainty regarding their ability to 
perform it properly. Similar difficulty was also cited as the primary reason for withdrawing from 
the study in all participants who left the study early due to “loss of interest. “ 
Five out of 14 participants who completed the study reported a history of 
anxiety/depression (2 in the control group, 3 in the intervention group). The two participants with 
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a history of anxiety/depression in the control group reported a comparable rate of compliance 
(89% and 94%) to the average group rate of compliance (87%).  In the experimental group, the 
three participants with a history of anxiety/depression reported an average rate of compliance of 
64%, which was lower than the average rate of compliance (82%) of the group. Furthermore, one 
participant in the experimental group whose data was excluded from analysis due to low 
compliance reported a history of anxiety/depression.   
The comparisons of baseline scores between the two groups in PDSS-2 overall score and 
sub-scores, and UPDRS overall score and sub-scores, found no significant differences. Averaged 
group means in PDSS-2 overall score and sub-scores increased in the control group, but 
decreased in the intervention group after the intervention (Figure 1). The primary measurement 
of sleep quality, PDSS-2 overall score, showed significantly (p<0.05) greater improvement in the 
intervention group compared to control group (Table 3-2). Significant difference between two 
groups was also found in the change of a sub-score of the PDSS-2, PD symptoms at night 
(p<0.05). Comparisons in other sub-scores between the two groups were found approaching 
significance in motor symptoms at night (p=0.071) and disturbed sleep (p=0.14). No significant 
differences were observed between two groups in changes in UPDRS overall score and sub-
scores (Table 3-2). Nevertheless, while the control group’s scores remained virtually unchanged 
between pre- and post-intervention, the mean values of the experimental group changed by 
14.21% (from 51.71 to 44.36) for overall UPDRS score, and 17.46% (from 30.29 to 25.00) for 
its motor function sub-score, even though statistically insignificant. An examination of statistical 
powers for the two tests revealed only 17.4% power for UPDRS total and 11.5% power for 
motor function sub-score, respectively. 
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For secondary measurements, no significant difference in baseline values and changes 
between two groups were observed in scores of NMSS, GDS, GAS, TMT-A, TMT-B, MMSE, 
FAB, PFS, and PDQ-39 (Table 3-3). However, in a close examination of trends, some measures 
showed a tendency for improvement, including depression (p=0.144), fatigue (p=0.179), and 
cognitive functioning as measured by the trial-A test (p=0.078) and frontal assessment battery 
(p=0.101) (Figure 2).  
No significant differences in gait performance measurements between the two groups 
were detected when comparing the changes in measured variables (Table 3-5). Within-group 
differences in pre- and post-intervention comparisons showed similar trends in the two groups.  
There was a same component between two groups, the smooth body movements under a 
structured daily exercise program. To better examine changes in gait performance after the 
intervention, we combined the data from both groups into one dataset and found a significant 
changes post intervention compared to baseline in velocity, step time, swing time, and single 
support time (Table 3-5). Mean velocity increased (+9.96%, p=.037) while step time (-5.92%, 
p=.046), swing time (-7.35%, p=.031) and single support time (-7.35%, p=.031) all decreased, 
indicating improvement in gait functionality. Step length (+4.12%, p=.070), stride length 
(+4.16%, p=.068), and stance time (-4.18%, p=.072) all approached significance.  
Discussion 
In this pilot study, we gathered information about the feasibility of a Qigong exercise 
program and its potential benefits in patients with PD. The compliance rates of our Qigong 
exercise or sham Qigong exercise programs were equal or greater than 72%, on average more 
than one session per day.  No adverse effects resulted from the practice of either Qigong or sham 
Qigong exercise. As mentioned, the experimental group’s lower compliance occurred during the 
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first two weeks after the initial training session. Some participants complained about the 
difficulty in memorizing the Qigong exercise, which was also cited as a primary issue in dropout 
cases in the intervention group. A possible solution for this issue is to slow down the pace of 
training activities in future trials for the specific target population. 
Mood symptoms may have influenced the rate of compliance for the Qigong exercise. 
Past studies have reported that mood symptoms affect the compliance of a prescribed home-
based exercise routine in patients with PD.[10] In the current study, participants with a history of 
anxiety and depression in the intervention group reported lower rates of compliance compared to 
the rest of the group. Rates of compliance in participants with a history of anxiety/depression in 
the control group, however, were not lower than that in the rest of the group. Compared to the 
sham Qigong, additional components and their synchronization of the Qigong exercise 
(regulating breath, meditation, and synchronized sounds) might make it more difficult for 
participants to learn and memorize, especially for those with anxiety/depression. Such difficulty 
was the complaint of those who dropped out of the intervention group. Given the fact that mood 
symptoms are quite common in patients with PD, we may increase the length of training period 
to slow down the pace of training activities and provide more group practice opportunities to 
participants in future trials.  
Our results indicated that the Qigong exercise with daily home sessions may improve 
sleep quality. Sleep dysfunction as evaluated by PDSS-2 in the form of motor symptoms at night, 
PD symptoms at night, and disturbed sleep, are common to PD patients. [3, 8, 13, 36] In the 
current study, Qigong exercise improved sleep quality based on significant difference in changes 
in PDSS-2 total score and score of PD symptoms at night in comparison to the sham Qigong 
exercise. In addition, the scores of motor symptoms at night and disturbed sleep showed a trend 
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towards significant improvement in the experimental group compared to the control group. 
These results would suggest the combined components of deep breath, meditation, and rhythmic 
body movements in Qigong positively benefit sleep quality in patients with PD. In our previous 
study in a single group of patients with PD, we observed a significant improvement in sleep 
quality after Qigong exercise compared to baseline measurement.[38] The current randomized 
pilot trial used the same intervention and confirmed our previous finding through a comparison 
to a control group. This result agrees with a past randomized pilot trial reporting a reduction in 
sleep disturbance after Qigong exercise in persons with PD. [18] Past studies have also indicated 
that meditational exercise is associated with the release of neuro-hormones and other natural 
health recovery mechanisms.[17] Future studies with large sample sizes are required to further 
examine findings of our pilot studies.   
The practice of Qigong exercise may alter the overall functionality in PD. Although not 
significantly significant, overall UPDRS score and motor function sub-score showed a trend 
towards an significant improvement in the intervention group, but not the control group. The 
sample size of the current pilot study may be an limiting factor. A few studies have reported 
mixed results on UPDRS score after Qigong exercise. A past pilot study reported that Qigong 
exercise did not significantly improve disease severity in PD. [21].  A different study used an 
intervention of weekly Qigong session of 90 minutes for 6 months and reported significant 
improvement in UPDRS motor score.[18]  The short trial period in the current study may discern 
potential comparative benefits of the Qigong exercise. Observable improvement of motor 
symptoms resulting from Qigong exercise may possibly require a longer period of time for 
intervention and a larger sample size in future trials.  
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The improvement in cognitive functioning, fatigue and depression in the Qigong exercise 
group approached a significant difference between two groups. Past studies have suggested that 
fatigue and cognitive impairment are related to each other in PD, suggesting improvement in one 
aspect may lead to similar improvement in its related aspect.[7, 15] A previous study testing the 
effects of Qigong exercise in patients with fibromyalgia suggest improvement in fatigue. [40] 
While Qigong exercise can offer therapeutic effects for the anxiety and depression in general 
population [41], some recent studies indicated such potential in patients with PD. [18, 21, 42] It 
has been suggested that  the earlier the alternative therapies are introduced for anxiety and 
depression, the more effective they are. [13] The small sample size is a limiting factor in the 
current study. More studies with larger sample sizes are therefore needed to develop effective 
approaches to improve fatigue, cognitive function, and mood in PD.[7] 
No group differences were observed in measured variables of gait performance, however, 
it was apparent in data analysis that participants in both groups showed improvement after the 
intervention in comparison to baseline measurement. The combined data from two groups 
showed statistically significant changes in velocity and step time between pre- and post-
intervention measurements, and changes in step length and stride time approached significance. 
Both groups in the current study performed the same mild body movements on a daily basis. 
Slower velocity as well as shortened step length during walking have been associated with gait 
impairment in PD. [13, 22, 23] Sufficient evidence suggests that regular physical exercise has a 
positive impact on PD. [43, 44]  A recent randomized controlled trial of 195 participants with 
mild to moderate PD found that Tai Chi training was superior to resistance training and 
stretching for improvement in measurements of postural stability, stride length, functional reach, 
and other motor function impairment. [45, 46] Further, overall well-being and gait variability 
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have been shown to improve with the practice of Tai Chi in PD. [47] The mild body movement 
involved in our interventions were similar to some body movements in Tai Chi exercise. The 
result of the current study suggested that the structured daily practice of the mild body 
movements, a component of the Qigong exercise, may lead to improvement in gait performance 
in patients with PD.  
Limitations: The current study had a number of limitations.  Small sample size restricted the 
strength of current findings, the statistical power in data analysis, and generalizability of the 
results. The rate of exercise compliance was also an issue, especially as it related to history of 
anxiety and depression. In order to deal with compliance issues, future trials should consist of 
slow paced training activities and increased number of Qigong sessions, and longer duration. 
Individualized consultation sessions focusing on anxiety/depression may be helpful too and 
boost participants’ interest, confidence, and overall compliance.  
Conclusions: Results of the current study suggest that Qigong exercise may be a viable 
alternative therapy for sleep dysfunction and other symptoms including possibly fatigue and 
cognitive dysfunction in PD. A history of anxiety and depression may influence the rate of 
compliance and therefore the efficacy of the Qigong exercise. While these aspects of our 
hypothesis were confirmed, the Qigong exercise was not shown to improve gait pattern 
compared to an exercise program with the same physical movements.  However, the study 
findings suggest the mild smooth body movement component of Qigong may potentially 
improve gait performance.  Qigong exercise was shown to be tolerable for long-term home-based 
practice without any adverse side effects. Future clinical trials with more participants and longer 
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Figure 1. Mean and standard error of the mean (SEM) of changes in the intervention and control 
groups in the PDSS-2 overall score and sub-scores in PD symptoms at night, motor symptoms at 




















Figure 2. Mean and standard error of the mean (SEM) of changes in the intervention and control 





















Table 3-1 Group Characteristics and Rates of Compliance 
Mean and standard deviation characteristics of each group’s participants based on self-reporting 
prior to the intervention.  Mean and standard deviation exercise compliance is based on the 
percentage sessions completed out of morning, evening, and total sessions. 
  Baseline Characteristics Exercise Compliance 







Morning       
(% Complete) 
Evening       
(% Complete) 
Control 7 67.0 ± 7.8 57%/43% 10.1  ± 3.6 29% 89% ± 11% 84% ± 14% 
























Table 3-2 Primary Outcome Measures of Sleep Quality 
Revised Parkinson’s Disease Sleep Scale (PDSS-2) scores and United Parkinson’s Disease 
Rating Scale (UPDRS) scores for both control and experimental groups. Sub-scores for each 
scale are also included. Mean ± standard deviation for pre- and post-intervention testing are 
given for total and sub-scores of each scale. Higher scores indicate more severe symptoms of the 
category. Categories in bold are those with significant difference (p<.05) based on between 








Pre Post Pre Post p-value 
PDSS-2 Total 13.3 ± 8.6 19.5 ± 11.1 17.1 ± 10.0 13.6 ± 8.0 0.048 
Motor Symptoms at Night 3.2 ± 2.1 4.3 ± 4.2 4.7 ± 4.6 3.0 ± 2.6 0.071 
PD Symptoms at Night 2.8 ± 1.8 4.2 ± 3.9 4.4 ± 3.2 3.0 ± 2.4 0.038 
Disturbed Sleep 8.0 ± 4.4 11.0 ± 5.3 8.0 ± 4.4 7.6 ± 5.1 0.141 
UPDRS Total 39.1 ± 17.2 40.0 ± 18.1 51.7 ± 32.2 44.4 ± 25.5 0.1705 
Mentation, Behavior, and Mood 7.3 ± 4.4 7.9 ± 3.6 8.1 ± 4.3 7.6 ± 4.3 0.2536 
Activities of Daily Living 10.3 ± 3.0 10.7 ± 4.9 11.3 ± 7.1 9.6 ± 4.3 0.2061 
Motor 19.7 ± 12.1 19.1 ± 11.0 30.3 ± 24.6 25.0 ± 23.8 0.2354 

















Table 3-3 Secondary Outcome Measures of Non-Motor Symptoms 
Non-Motor Symptom Geriatric Depression Scale (GDS), Geriatric Anxiety Scale (GAS), Trail 
Making Test parts A (TMT-A) and B (TMT-B), Mini-Mental State Exam (MMSE), Frontal 
Assessment Battery (FAB), Parkinson’s Fatigue Scale (PFS), and Parkinson’s Disease 
Questionnaire (PDQ-39) scores for both control and experimental groups. Mean ± standard 
deviation for pre- and post-intervention testing are given. Higher GDS, GAS, TMT-A, TMT-B, 
and PFS scores indicate more severe symptoms while lower MMSE, and FAB scores indicate 
greater cognitive impairment. Higher PDQ-39 scores indicate lower quality of life in relation to 






Pre Post Pre Post 
GDS 5.43 ± 2.88` 5.33 ± 3.08 7.43 ± 5.65 6.29 ± 6.07 0.2577 
GAS 3.29 ± 1.80 3.50 ± 1.38 4.14 ± 3.02 4.14 ± 3.34 0.3180 
TMT-A  40.00 ± 14.79 40.86 ± 9.46 62.29 ± 31.53 52.86 ± 32.63  0.0776 
TMT-B 113.29 ± 68.33 96.71 ± 44.57 123.71 ± 75.10 106.00 ± 49.73 0.4805 
MMSE 28.86 ± 1.57 29.07 ± 1.02 29.71 ± .49 29.50 ± .76 0.2558 
FAB 16.29 ± 1.70 14.71 ± 2.81 17.14 ± 1.21 17.00 ± 1.00 0.0809 
PFS 47.14 ± 15.13 50.00 ± 9.93 45.86 ± 19.43 40.86 ± 23.67 0.0846 
















Table 3-4 Gait Impairment 
Gait performance for both control and experimental groups, and for combined data set. Mean ± 
standard deviation is given for pre and post intervention measures. P-values comparing 
difference in change of gait measures are given. Significant measures (p<.05) are given in bold. 
 
 





Pre Post Pre Post 
Velocity (m/s) 1.01 ± .13 1.14 ± .21 .96 ± .20 1.02 ± .12 0.2756 
Step Time (s) .58 ± .02 .54 ± .07 .61 ± .08 .58 ± .03 0.3469 
Swing Time (s) .47 ± .05 .42 ± .05 .46 ± .06 .44 ± .04 0.2144 
Step Length (m) .58 ± .09 .61 ± .11 .58 ± .09 .59 ± .06 0.3394 
Stride Length (m) 1.17 ± .18 1.24 ± .22 1.17 ± .18 1.24 ± .22 0.3255 
Stance Time (s) .67 ± .07 .65 ± .10 .67 ± .07 .65 ± .10 0.2515 
 Combined dataset 
 pre Post p-value  % change 
Velocity (m/s) 0.99 ± .16 1.09 ± 0.2 0.0369 9.96% 
Step Time (s) 0.59 ± .06 0.6 ± 0.1 0.0460 -5.92% 
Swing Time (s) 0.46 ± .05 0.4 ± 0.04 0.0305 -7.35% 
Step Length (m) 0.58 ± 0.1 0.6 ± 0.1 0.0703 4.12% 
Stride Length (m) 1.16 ± 0.2 1.21 ± 0.2 0.0684 4.16% 














Chapter 4: Conclusion 
Summary of Findings 
The database statistical analysis confirmed previous findings that anxiety and depression are 
indeed relevant features of PD.[1-5] Prevalence of co-existing anxiety and depression, as 
measured by the co-morbidity rate of both mood symptoms (45%), was found to be higher than 
previously estimated, while 66% and 49% of the sample population reported relevant anxiety and 
depression symptoms, respectively, and 70% reported one or both symptoms.[6-8] The rate of 
anxiolytic and anti-depressant use was 18% and 31%, respectively, while more than three fourths 
of persons reporting taking medication for mood disorders still reported anxiety or depression 
symptoms. These results both suggest the therapeutic impact of this medication may be limited.  , 
Mild depression overall, at a rate of 33%, was also found to be higher than previously reported, 
and mood symptoms tended to be more prevalent in subjects with more advanced PD.[2, 9, 10] 
These findings support the hypothesis that serotonergic degeneration, often primarily linked to 
mood symptoms, may also be associated with the neuropathology of PD, but progress non-
linearly with respect to disease severity. [11, 12]   
The clinical trial revealed the mild exercise Qigong as a potentially beneficial 
complementary therapy for treating sleep dysfunction, a common complaint with persons 
diagnosed with PD.[13-17] However, participants with a history of anxiety/depression seemed to 
have greater difficulty with consistently practicing the home-based Qigong exercise, as revealed 
by their lower average rate of compliance.[18] After the six-week intervention period, sleep 
quality measures significantly improved in the intervention group who practiced Qigong 
compared to a control group practicing a sham form.  Findings confirm the previous pilot study’s 
results, and additionally, the experimental group’s motor, cognitive functioning, fatigue, and 
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depression symptoms approached significance in terms of comparative improvement. [17] Both 
groups improved velocity, step time, stride length, and autonomic NMS related to PD, which 
suggests mild, regular physical exercise improves these aspects in PD.[19, 20]  While aspects of 
the Qigong exercise may improve gait impairment in PD, such as the smooth movements or 
regular exercise, the hypothesis that Qigong exercise results in improved gait pattern cannot be 
confirmed.  
Thus, a response to the original research question, ”how do mood symptoms in PD impact 
the efficacy of alternative therapy program Qigong exercise program for treating motor and non-
motor aspects of the disease?” can be put forth in light of these two studies. Taken together, the 
findings confirm the hypothesis put forth that mood symptoms affect a substantial number of 
persons with PD and may impact the efficacy of therapies for treating aspects of the disease. [1, 
3-5, 18, 21, 22] Given how prevalent mood symptoms were found to be in the PD population and 
the limited impact of current treatment for these systems, addressing these symptoms may 
improve the overall effectiveness of alternative therapies such as the Qigong therapy examined 
in this study.[21, 23] Even still, this feasibility study has shown that Qigong exercise is a 
promising complementary therapy for treating sleep dysfunction and potentially other non-motor 
symptoms in PD.[24] 
 
Clinical Implications 
Findings from the database analysis indicate motor function is still a greater indicator to overall 
disease severity than mood symptoms when compared to mood or quality of life. Nevertheless, 
study findings suggest two out of every three persons diagnosed with PD have anxiety, while 1 
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out of two persons have depression. The non-linear progression of mood symptoms with respect 
to disease severity results indicate severity of serotonergic degeneration increases 
asymmetrically with respect to dopaminergic degeneration most closely associated with PD.[11, 
12]  Regardless, developing diagnostic tools and therapies for better identifying, recognizing, 
and treating mood disorders in PD is essential for providing adequate care.[2, 25-27]  
The influence of mood symptoms on the efficacy of Qigong exercise in PD patients can 
be speculated as the following. Our data showed that mood symptoms correlated with decreased 
compliance in Qigong exercise.  This finding suggests that anxiety and depression may affect the 
efficacy of alternative exercise programs. Stemming from the asymmetric serotonergic 
degeneration associated with PD, heightened symptoms of anxiety and depression may decrease 
the adherence with the intervention and therefore inhibit the positive effects of the Qigong 
exercise.[11, 12, 18]  While not specifically assessed in the database analysis, lower compliance 
with treatment among persons with anxiety or depression, which constitute a majority of the 
population of persons with PD, may partially explain why persons prescribed 
anxiolytics/antidepressant still reported experiencing relevant mood symptoms.[18, 28]  With 
respect to enhancing compliance with alternative exercise programs in PD, shared decision-
making coupled with a collaborative, reflective process between patients, caretakers, and 
physicians may improve adherence outcomes. For example, a patient and caretaker may work 
together to develop a daily schedule that includes time for complying with prescribed therapies 
for treating PD.  Further, physicians can provide a list of possible alternative, complementary 
therapy program options that are available for the patient and discuss which therapy would be 
most beneficial. [29] 
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Based on other findings of our study, a conceptual model can be put forth explaining the 
relationship between dopaminergic dysfunction, cognitive dysfunction, sleep disorder, gait 
variability, and the implementation of the Qigong exercise in PD. Given that gait impairment 
correlates strongly with cognitive decline, neurodegeneration associated with PD may result in 
cognitive dysfunction that compromises the ability for regulating walking tasks, thereby 
affecting gait pattern.[30-32] Further, sleep dysfunction, specifically RBD, is associated with 
slowness of gait, a symptom of hypokinesia, as well as increased risks for falling and decreased 
clinical efficacy of dopaminergic treatments.[33-36] By releasing neuro-hormones, the practice 
of Qigong exercise may improve primarily sleep quality as well as potentially cognitive 
functioning, fatigue, and depression and thus mitigate neurodegeneration potentially caused by 
ROS associated with PD. [28, 37] In addition, the positive effects due to body physical 
movement in an exercise program may improve deficits in the automaticity of gait associated 
with PD.[19, 20] 
Limitations 
The database’s cross-sectional design only allowed for correlational analysis between disease 
severity, quality of life, and mood disorders.  Thus, a causal relationship between these features 
of the disease and disease progression could not be established.  Further, the source-analyzed 
data comes from complete examinations in a clinical setting, which may not adequately represent 
the population of persons with PD.  Similarly, results from clinical trial are limited due to the 
study participants consisting of persons who voluntarily completed the study and were able to 
transport themselves to the clinic.  Participants dropping out of the study early, and the initial 
low compliance rate of the experimental group also limit the viability of findings.  However, 
lower compliance did shed light on the possible effects anxiety and depression have on efficacy 
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of the exercise.  Finally, the small sample size (n=16), removal of two subject’s data due to low 
compliance, and loss of extraneous gait data due to equipment malfunctioning (Gaitmat data 
stored from one subject could not be analyzed) also limit the implications of this study. 
Future Directions 
Given the promising results of Qigong as a viable therapy for sleep dysfunction, more trials are 
required to better understand and apply the potential benefits of the mind-body exercise as an 
alternative, complementary therapy for both motor and non-motor symptoms in PD. As noted, 
mood symptoms remain relevant features of PD both in their prevalence and impact on the 
efficacy of potential therapies for PD.  Given the found limitations of the clinical trial, a future 
research project would further examine the potential benefits of Qigong exercise on persons with 
PD.  Both the pre-clinical and clinical period would be extended, where participants would have 
a month of practice sessions before the formal clinical trial would begin.  During the pre-clinical 
period, more time could be devoted to practicing the exercise during the weekly group sessions.  
Further, compliance could be enhanced by giving participants a more specific practice regimen 
during this time, such as only practicing part of the exercise during the first weeks of the pre-
clinical trial.  A future study would include targeted, patient-centered interventions that 
specifically address factors, specifically anxiety and depression, in order to enhance adherence 
with therapies treating PD.[29]    
A longer study duration would also allow for a longitudinal study design, where the 
change in symptoms could be monitored. Such a trial with greater sample size may also shed 
light on how Qigong exercise may slow, halt, or even reverse the overall progression of motor 
and non-motor components of disease severity.[24, 38] Additionally, different tools for assessing 
gait variability such as using the Vicon system for examining gait pattern with respect to turning 
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tasks, and employing visual cues in testing may better identify and elucidate gait disturbances in 
PD.[39] Enhanced tools for understanding the non-motor symptoms of PD and potential 
alternative therapies are therefore essential for providing adequate care for persons diagnosed 
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NAME: DATE OF BIRTH: 
First MI Last 
ADDRESS: 
StreetAddress 
City State Zip 
HOME #: ( ) - CELL #: ( ) - 
EMAIL 
1. What is your Marital Status 
Married Single Plan Marriage 
Divorced Separated Widowed 
2. What is the highest level of education you have completed? 
High school degree Doctorate 
Associate degree Professional (MD, JD, DDS, etc) Bachelor’s degree - Other (specify) 
Master’s degree None of the above (less than high school) 
3. Which of the following best describes your current main daily activities and/or 
responsibilities? 
Working full time _ Looking for work _ Working part-time _ Keeping house or raising 
children full-time 
Unemployed or laid off Retired 
4. With regard to your current or most recent job activity, in what kind of business or 
industry do (did) you work? 
(For example: hospital, newspaper publishing, mail order house, auto engine manufacturing, 
breakfast cereal manufacturing, etc) 











you do? (Job Title) 
How often (1x/day, 3x/week, etc) 
(For example: registered nurse, personnel manager, supervisor of order department, gasoline 
engine assembler, grinder operator, etc.) 
Do you smoke cigarettes? 
YES NO 
If yes, how many packs per day? 
Do you drink alcohol? 
YES NO 
If yes, how many drinks? /day /week /month 
How much caffeine do you consume in an average day? 
Coffee, # ounces 
Tea, # ounces 
Caffeinated soda, # ounces 
Do you exercise regularly? 
YES NO 
What type of exercise? 
Outside of exercise, how would you rate your daily activity level? 
High activity Low activity 
Moderate activity Little or no activity 
How long have you had Parkinson’s disease? 
Time since onset of symptoms 
Time since diagnosis 












Cancer (list type) 
Alcohol/Drug Abuse 
Current medication list 
NO YES 
















Please complete the following 
Please fick one box for each question 
Due to having Parkinson's disease, how often during the Jast month 
have you.... Never Occasionally Sometimes Often Always 
or cannot do 1 Had 
difficulty doing ! at all 
the leisure activities which you would like to do? 
2 Had difficulty looking after 
your home, e.g., DIY, housework, cooking? 
3 Had difficulty carrying bags 
of shopping? : 
4. Had problems walking half | a mile? - 
5 Had problems walking 100 - 
yards? 
6 Had problems getting 
around the house as easily as you would like? 
7 Had difficulty getting 
around in public? 
8 Needed Someone else to 
accompany you when you went out? 
9 Felt frightened or worried 
about falling over in public? 
10 Been confined to the house more than you would like? 
11 Had difficulty washing 
yourself? 
12 Had difficulty dressing - yourself? 
13 Had problems doing up 
your shoe laces? 
Please check that you have ticked one box for each question before going on to the next page 







Due to having Parkinson’s disease, 
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how offen during the last month 
have you.... Never 
14 Had problems writing | 
clearly? 
15 Had difficulty cutting up 
your food? 
16 Had difficulty holding a 
drink without spilling it? 
17 Felt depressed? 
18 Felt isolated and lonely? 
T 
19 Felt weepy or tearful? 
T 
20 Felt angry or bitter? 
21 Felt anxious? 
22 Felt worried about your 
future? 
23 Felt you had to conceal 
your Parkinson's from people? 
24 Avoided situations which 
involve eating or drinking in public? 
25 Felt embarrassed in public 
due to having Parkinson's disease? 
26 Felt worried by other 
people's reaction to you? 
27 Had problems with your 
close personal relationships? 
28 Lacked support in the 
ways you need from your spouse or partner? 
if you do not have a spouse or 
partner fick here 
29 Lacked support in the 
ways you need from your family or close friends? 















: i i 
Please check that you have ticked one box for each question before going on to the next page 
р 
age 4 of 12 






Due to having Parkinson’s disease, Please tick one box for each question 
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how often during the last month have you.... Never Occasionally Sometimes Often Always 
| | | | || || 
30 Unexpectedly fallen asleep 
during the day? 
31 Had problems with your 
concentration, e.g. when reading or watching TV'? 
| | | | | - 
32 Felt your memory was t 
bad? 
i 33 Had distressing dreams or 
hallucinations? 
34 Had difficulty with your 
speech? 
35 Felt unable to 
communicate with people properly? 
36 Felt ignored by people? 
37 Had painful muscle 
cramps or spasms? | 
38 Had aches and pains in 
your joints or body? 
39 Felt unpleasantly hot or 
Cold? 
Please check that you have ticked one box for each question before going on to the next page 
Thank you for completing the PDQ 39 questionnaire 








PD NMS QUESTIONN.Al RE 
Name: ................... * * * * * * * * * * * * * * * * r n n w = a m + - - - - m a Date .......................... А9е: 
....................... 
Centre D: Male [] Female [] 
NON-MOVEMENT PROBLEMS IN PARKINSON'S The movement symptoms of Parkinson's are well 
known. However, other problems can sometimes occur as part of the condition or its treatment. It is 
important that the doctor knows about these, particularly if they are troublesome for you. 
A range of problems is listed below. Please tick the box ‘Yes' if you have experienced it during the past 
month. The doctor or nurse may ask you some questions to help decide. If you have not experienced the 
problem in the past month tick the 'No' box. You should answer ‘No’ even if you have had the problem in 
the past but not in the past month. 
Have you experienced any of the following in the last month? 
Yes No Yes No 1. Dribbling of Saliva during the daytime 
......................... [] [] 16. Feeling sad, low' or 'blue' .......................................... 口 ロ 
2. Loss or change in your ability to taste or smell .......... [] [] 17. Feeling anxious, frightened or panicky ....................... [] [] 
3. Difficulty swallowing food or drink or problems 18. Feeling less interested in sex or more 
with choking .............................................................. [] [] interested in sex .......................................................... D. [] 
4. Vomiting or feelings of sickness (nausea)................... [] [] 19. Finding it difficult to have sex when you try ............... [] [] 
5. Constipation (less than 3 bowel movements a 20. Feeling light headed, dizzy or weak standing 
week) or having to strain to pass a stool (faeces)......... D D from sitting or lying ..................................................... [] [] 
6. Bowel (fecal) incontinence ........................................... [] [T] 21. Falling .......................................................................... 口 口 
7. Feeling that your bowel emptying is incomplete 22. Finding it difficult to stay awake during activities 
after having been to the toilet ....................................., [ ] [] Such as working, driving or eating .............................. DI DI 
8. A sense of urgency to pass urine makes you 23. Difficulty getting to sleep at night or staying 
rush to the toilet .............. [] [] asleep at night ......................................... [] [] 
9. Getting up regularly at night to pass urine .................. [] [] 24. Intense, vivid dreams or frightening dreams .............., D D 
10. Unexplained pains (not due to known conditions 25. Talking or moving about in your sleep as if you 
such as arthritis) ........................................................... [] [] are 'acting' out a dream .............................................. [] 口 
11. Unexplained change in weight (not due to 26. Unpleasant sensations in your legs at night or 
Change in diet) ...................................................... [] [] while resting, and a feeling that you need to move .... [] [] 
12. Problems remembering things that have 27. Swelling of your legs ................................................... [] [] 
happened recently or forgetting to do things .............. [] [] 
28. Excessive sweating 
..................................................... [] [] 13. Loss of interest in what is happening around 
you or doing things ...................................................... [] [] 29. Doublevision ..., D D 
14. Seeing or hearing things that you know or are 30. Believing things are happening to you that other 
told are not there ........................................... [] [] people Say are not true ............................................... [] [] 
15. Difficulty concentrating or staying focussed ............... [] [] 
All the information you supply through this form will be treated with confidence and will only be used for the purpose for which 
it has been Collected. Information Supplied will be used for monitoring purposes. Your personal data will be processed and held 
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in accordance with the Data Protection Act 1998. 









Non-Motor Symptom assessment scale for Parkinson's disease 
Name Initial: Date: 
Symptoms assessed over the last month. Each symptom scored with respect to: Severity: 0 = None; 
1 = Mild: symptoms present but causes little distress or disturbance to patient; 2 = Moderate: some 
distress or disturbance to patient; 3 = Severe: major source of distress or disturbance to patient. 
Frequency: 1 = Rarely (<1/wk), 
2 = Often (1/wk), 3 = Frequent (several times per week); 4 = Very Frequent (daily or all the time). 
(Bracketed text in questions within the scale is included as an explanatory aid). 
Severity 
Frequency Domain 1: Cardiovascular including falls 1. Did you experience light-headedness, dizziness, 
weakness 
on standing from sitting or lying position? [ ] [ 
|
 2. Did you fall because of fainting or blacking out? [ ] [ ] 
Domain 2: Sleep/fatigue 3. Did you doze off or fall asleep unintentionally during daytime 
activities? (For example, during conversation, during mealtimes, or [ ] [ ] while watching television or 
reading). 
4. Did fatigue (tiredness) or lack of energy (not slowness) limit your 
daytime activities? [ ] [ ] 
5. Did you have difficulties falling or staying asleep? - [ ] [ ] 
6. Did you experience an urge to move the legs or Restlessness in 
legs that improves with movement when he/she is sitting or lying down inactive? [ ] [ ] 
Domain 3: Mood/cognition 
7. Has you fost interest in his/her surroundings? [ ] [ ] 8. Has you lost interest in doing things or lack 
motivation to 
start new activities? [ ] [ ] 9. Did you feel nervous, worried or frightened for no 
apparent reason? [ ] [ ] 10. Did you seem sad or depressed or has he/she reported 
such feelings? [ ] [ ] 11. Did you have flat moods without the normal “highs" 
and “lows"? - [ ] [ ] 12. Did you have difficulty in experiencing pleasure from 
their usual activities or report that they lack pleasure? [ ] [ ] 
Domain 4: Perceptual problems/hallucinations 13. Did you indicate that he/she sees things that are not 






14. Did you have beliefs that you know are not true? 
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(For example, about being harmed, being robbed or being unfaithful) 
15. Did you experience double vision? 
(2 separate real objects and not blurred vision) 
Domain 5: Attention/memory 16. Did you have problems sustaining concentration during activities? 
(For example, reading or having a conversation) 
17. Did you forget things that he/she has been told a short time ago or events that happened in the last few 
days? 
18. Did you forget to do things? 
(For example, take tablets or turn off domestic appliances?) 
Domain 6: Gastrointestinal tract 19. Did you dribble saliva during the day? 
20. Did you have difficulty swallowing? 
21. Did you suffer from constipation? 
(Bowel action less than three times weekly) 
Domain 7: Urinary 22. Did you have difficulty holding urine? (Urgency) 
23. Did you have to void within 2 hours of last voiding? (Frequency) 24. Did you have to get up 
regularly at night to pass urine? (Nocturia) 
Domain 8: Sexual function 
25. Did you have altered interest in sex? 
(Very much increased or decreased, please underline) 
26. Did you have problems having sex? 
Domain 9: Miscellaneous 
27. Did you suffer from pain not explained by other known conditions? 
(Is it related to intake of drugs and is it relieved by antiparkinson drugs?) 
28. Did you have a change in ability to taste or smell? 
29. Did you have a recent change in weight (not related to dieting)? 
30. Did you experience excessive sweating (not related to hot weather)? 
TOTAL SCORE: Developed by the International Parkinson's Disease Non-Motor Group. 














Parkinson's Disease Sleep Scale (PDSS-2) 
Name Initial: Date: 
Please rae the severity of the following based on your experiences during the past week (7 days). Please 
make a cross in the answer box. 
Very often Often Sometimes Occasionally Never (6 to 7 days (4 to 5 days (2 to 3 days (1 day a week) 
a week) a week) a Week) 
1. Overall, did you sleep well during the last week? Do []" []2 D3 D4 2. Did you have difficulty falling asleep each 
night? П4 []3 [12 DA  0 3. Did you have difficulty staying asleep? D4 D3 [12 [14 По 4. Did you have restlessness 
of legs or arms at night D4 D3 П2 D4 Clo 
causing disruption of sleep? 
5. Was your sleep disturbed due to an urge to move D4 Cl3 D2 D4 По 
your legs or arms? 
6. Did you suffer from distressing dreams at night? D4 D3 D2 [] Do 7. Did you suffer from 
distressing hallucinations at night D4 D3 D2 D4 По 
(seeing or hearing things that you are told do not exist)? 8. Did you get up at night to pass urine? D4 [13 D2 D4 
Do 9. Did you feel uncomfortable at night because you п4 Пз D2 D4 Do 
were unable to turn around in bed or move due to immobility? 
10. Did you feel pain in your arms or legs which woke D4 D3 口2 [14 00 
you up from sleep at night? 
11. Did you have muscle Cramps in your arms or legs П4 D3 D2 미1 00 
which woke you up whilst sleep at night? 
12. Did you wake early in the morning with painful D4 D3 D2 [14 Do 
posturing of arms or legs? 
13. On waking, did you experience tremor? П4 Tl2 D2 Па По 
14. Did you feel tired and sleepy after Waking in D4 D3 [12 D4  0 
the morning? 
15. Did you Wake up at night due to Snoring or D4 []3 D2 D1 По 
difficulties with breathing? 
 
